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ABSTRACT 
Cardiovascular diseases (CVD) are the number one cause of death worldwide. 
About one fifth of those who survived a myocardial infarction will suffer a recurrent 
cardiovascular event (CVE). Given the low participation in recommended cardiac 
rehabilitation, there is interest in early risk stratification after a primary CVE. This 
dissertation evaluates leisure time physical activity (LTPA), N-Terminal pro-Brain 
Natriuretic Peptide (NT-proBNP) and cystatin C as predictors of a secondary CVE in a 
German cohort of cardiac rehabilitation patients with stable coronary heart disease 
followed from 1999 to 2008. 
 
Study 1 evaluated self-reported LTPA at one-year follow-up. Those reporting 
seldom/never practice of LTPA showed a higher risk (Hazard Ratio (HR) 1.30 [95% 
Confidence Interval (CI) 0.62, 2.69]), while those reporting LTPA at least 5-6 
times/week had a reduced risk (HR 0.88 [95% CI 0.54, 1.43]) for a subsequent CVE, 
when compared to the reference group (1-4 times/month). Study 2 examined LTPA 
trajectories during the age period 20-49 years. Compared to those with a gradual decline 
of LTPA, the highest risk was observed among those with a steeper decrease of LTPA 
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(HR 1.59 [95% CI 0.97, 2.62]). A continuous increase of LTPA was associated with a 
risk reduction (HR 0.71 [95% CI 0.41, 1.22]) with respect to a recurrent CVE. 
 
Studies 3 and 4 evaluated the prognostic value of two novel biomarkers, when 
added to a model containing well-established CVD risk factors. In Study 3, NT-proBNP 
levels at one-year follow-up and a 10% increase in the slope of a NT-proBNP three-year 
trajectory were associated with a subsequent CVE ,with HRs of 1.63 [95% CI 1.17, 2.27] 
and 1.24 [95% CI 1.12, 1.37], respectively. One-year, but not baseline, levels of NT-
proBNP showed an improvement in risk reclassification. Study 4 examined cystatin C 
versus creatinine. Although both were associated with a recurrent CVE, only the addition 
of cystatin C improved model performance, discrimination and reclassification. 
 
In conclusion, in patients with stable coronary heart disease, LTPA, NT-proBNP, 
and cystatin C might help to identify individuals at high risk for a recurrent CVE. Further 
research is needed to evaluate treatment modalities for secondary prevention in this 
group. 
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INTRODUCTION 
Cardiovascular diseases (CVD) are the number one cause of death worldwide. 
About 17.5 million people died from CVD in 2008, 7.3 million due to coronary heart 
disease (CHD) and 6.2 million due to stroke1. Each year about 770,000 Americans2 and 
280,000 Germans3 suffer a myocardial infarction (MI), with 295,000 Americans having a 
recurrent attack2. In the first five years after an initial MI, 15% of men and 22% of 
women 45 to 64 years of age and 22% of all individuals older than 65 years of age will 
suffer a recurrent cardiovascular event (CVE)4. 
 
All eligible patients with acute coronary syndrome or immediately post coronary 
artery bypass surgery (CABG) should be referred to a comprehensive cardiovascular 
rehabilitation program5-7. Cardiac rehabilitation represents a secondary preventive 
program5,8 recommended by the American Heart Association, American College of 
Cardiology, and European Society of Cardiology for the treatment of CHD and chronic 
heart failure6, 7, 9-11. Unfortunately, only 14 to 35% of heart attack survivors and 31% of 
patients after CABG participate in such a program in the US12, 13. In Germany, cardiac 
rehabilitation offered as a comprehensive three-week in-hospital rehabilitation program, 
usually starting 2-3 weeks after the acute event, also shows low participation rates (20% 
among those 55-65 years; 10% for those older than 65 years)14. Given these low rates of 
participation, an early risk stratification of patients directly after a primary CVE becomes 
essential in order to guide their treatment and improve their outcomes. This dissertation 
examines the association between leisure time physical activity (LTPA) as well as the 
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prognostic value of N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) and cystatin 
C with respect to the onset of a secondary CVE in a cohort of patients with CHD who, 
following an acute coronary syndrome participated in a cardiac rehabilitation program. 
 
Physical inactivity is one of the important risk factors for heart disease15, where 
increasing amounts of physical activity have been associated with a risk reduction for 
CVD16. However, the role of physical activity in secondary prevention has been mainly 
examined in the settings of randomized clinical trials of cardiac rehabilitation programs 
and usually performed among white male MI patients17, 18, with a marginal representation 
of women19-21. The available observational studies are based mostly on small samples, 
which has not allowed an evaluation of a dose-response due to the low number of 
subjects across the strata of physical activity19-22. The first study of this dissertation 
examines the association of LTPA and the onset of a secondary CVE. We evaluated the 
association between the self-reported LTPA at one-year follow-up and the subsequent 
onset of a CVE. Based on the fact that any increase in the levels of physical activity, even 
if initiated at older age, may result in a strong reduction in the risk of a primary CVE23, 24, 
the second study explores the association between  LTPA trajectories for the age-period 
20-49 years and the association with the onset of a secondary CVE. 
 
The third study of this dissertation examines the prognostic value of NT-proBNP, 
a well-established marker for myocardial hemodynamic stress, in the setting of secondary 
prevention. For the first analysis we evaluated the prognostic value of this biomarker 
  
3 
measured at baseline and at one-year follow-up with respect to the onset of a subsequent 
CVE among those who remained event-free after one year of follow-up. Having limited 
information with respect to the utility of serial measurements of NT-proBNP, the second 
analysis examines the association between a three-year NT-proBNP trajectory and the 
onset of a subsequent CVE among those who remained event free during the first three 
years of follow-up. 
 
The presence of renal dysfunction has been associated with cardiovascular 
damage. Vascular disease can contribute to a further deterioration of renal function, 
increasing the risk for a CVE25. In this context the fourth study of the dissertation relates 
to the prognostic value of cystatin C, a novel marker of kidney function, in contrast to the 
prognostic value of creatinine with respect to the onset of a secondary CVE.  
 
An important aim of this dissertation is the identification of new risk factors for 
the onset of a secondary CVE among cardiac patients, not only direct after the primary 
event but also during the following three years. This information might be useful in the 
early risk stratification of patients. 
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KAROLA COHORT 
The KAROLA (KARdiOLogische Anschlußheilbehandlung) Cohort is a 
prospective study of 1206 patients with CHD, ages 30-70 years, who were admitted 
within three months after an acute coronary syndrome to a three-week in-hospital cardiac 
rehabilitation program at two co-operating clinics located in Southwest Germany between 
January 1999 and May 2000. The study was approved by the ethics boards of the 
Universities of Ulm and Heidelberg and of the Physicians’ Chamber of the States of 
Baden-Württemberg and Hessen. All participants gave written consent. 
 
At the beginning of the rehabilitation program, all participants filled out a 
standardized questionnaire containing socio-demographic information, medical history 
and assessment of lifestyle including LTPA. Self-reported information on type of 
treatment (CABG versus Percutaneous Transluminal Coronary Angioplasty (PTCA)), 
secondary diagnoses and medications were validated with the patient’s hospital charts. 
Active follow-up was conducted at 1, 3, 4.5, 6, 8 and 10 years after discharge from the 
rehabilitation center using mailed standardized questionnaires (Figure 1). For the 
purpose of the study a stable cardiac participant was defined as a participant with no 
change in frequency, duration, precipitating causes or ease of relief of angina for at least 
60 days, without evidence of recent myocardial damage26. Fasting blood samples were 
obtained at the end of the rehabilitation program (baseline values) and at one- and three-
years follow-up. Samples were stored for up to one month at -20°C, and then transferred 
to a -80°C freezer until analysis.  
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Figure 1. KAROLA Cohort study design. 
 
DEFINITION OF THE OUTCOME 
The outcome included fatal and non-fatal CVEs. Primary care physicians 
completed standardized questionnaires at each follow-up, reporting any secondary CVE 
(non-fatal MI and/or stroke) and new treatment and/or diagnoses. For each follow-up the 
Residents’ Registration Office was contacted. Information on change of addresses and on 
deaths, including date of death and death district, was provided by this office. The 
corresponding Public Health Department was contacted, and the death certificates were 
collected. The main cause of death was coded according to the 9th (until 2003) and 10th 
International Classification of Diseases (ICD) (ICD-9 codes 390-459 until 2003, followed 
by ICD-10 codes I0-I99 or R57.0). All 145 secondary CVEs occurring over 10 years of 
follow-up were considered in the analyses. 
 
KAROLA Cohort 
End Cardiac 
Rehabilitation 
(Baseline)* 
1 year* 3 years* 4.5 years 6 years 8 years 
* Patient / PCP Questionnaire and collection of blood samples 
 Patient / PCP Questionnaire 
10 years 
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DEFINITION OF COVARIATES 
Baseline information on the following covariates were collected from the 
questionnaire performed at the beginning of cardiac rehabilitation: age, sex, level of 
education (<9 years school, ≥9 years school), marital status (single, married, divorced, 
widow), smoking (never, past, or current smoker), alcohol intake (low consumption, 
equivalent to ≤ 13.9 g/week; moderate consumption, 14.0 – 97.9 g/week for women and 
14.0-195.9 g/week for men; heavy consumption, ≥ 98.0 g/week for women and ≥196.0 
g/week for men)27, 28, body mass index (BMI) defined as the individual’s body weight 
divided by height squared (normal weight BMI <25.0 kg/m2, overweight BMI 25.0-29.9  
kg/m2, obese BMI  ≥30.0 kg/m2), severity of cardiac disease defined by the number of 
vessels affected (one, two or three), left ventricular function (normal, mild, moderate, and 
severely depressed), status post MI and status post CABG as reported by the discharge 
summary from the hospitalization related to the acute coronary syndrome, history of 
hypertension, history of diabetes, history of heart failure, self-assessed health status 
(good, regular and poor), and current use of several medications (yes/no) - angiotensin 
converting enzyme (ACE) inhibitors, aspirin, beta-blockers, diuretics, and/or statins. At 
one-year follow-up the following information was extracted from the questionnaires: 
current smoking (yes/no), alcohol consumption and BMI, history of hypertension, history 
of diabetes, history of heart failure, self-assessed health status (good, regular and poor), 
and current use of medications as previously listed. 
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Left ventricular (LV) systolic function at baseline was assessed using either the 
most recent LV angiography (n=707, 96.2%) or available echocardiographic 
examinations (n=644, 87.6%). When both examinations were available, the one reporting 
the lowest ejection fraction (EF) was considered.  When EFs were available, LV function 
was categorized into normal (>65%), mild (50-65%), moderate (35-50%) or severe 
depression (<35%). Prescribed medications on the discharge form were recorded. 
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LEISURE TIME PHYSICAL ACTIVITY AND THE ONSET OF A 
SECONDARY CARDIOVASCULAR EVENT  
 
Physical inactivity was recognized in 1992 by the American Heart Association as 
an important risk factor for heart disease15. As per the most recent American and 
European guidelines for secondary prevention of CVEs, all vascular patients should be 
encouraged to perform 30 to 60 minutes of moderate-intensity aerobic activity at least 
five, but preferably seven days a week, supplemented by an increase in daily lifestyle 
activities5, 11.  
 
Exercise training is known to have direct benefits on the development of collateral 
vessels, improvement of coronary endothelial function, autonomic tone, 
coagulation/inflammatory markers, and other risk factors for initiation and progression of 
atherosclerotic disease (blood pressure, lipid profile, glucose tolerance, smoking, weight 
and emotional state)29-33. Increasing amounts of physical activity seems to be associated 
with a risk reduction for CVD in both sexes; however, the dose-response curve for this 
relation has not been well defined16. A meta-analysis including 33 studies showed that 
with respect to CHD adults who engaged in the equivalent of 150 min/week of moderate-
intensity activity had a 14% risk reduction, while those who engaged in the equivalent of 
300 min/week had a 20% risk reduction when compared to sedentary adults34. In this 
context, only a few studies have examined the association between physical activity and 
CVEs in patient with established CHD19, 20, 22, 35-37. Most studies focused on the 
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evaluation of physical activity in the general population. These results cannot be easily 
transferred to CHD patients, who are characterized by a higher risk for adverse events, 
especially during vigorous exercise, as well as by the presence of symptoms which limit 
exercise 13. 
 
Physical activity behavior generally changes throughout the life-course; most 
individuals show a decline in overall leisure time physical activity (LTPA) over time38. 
However, it is relatively unknown whether those changes are gradual or are initiated by 
key life events38 and if these changes are associated with all-cause mortality39. Transition 
from primary to secondary school or from high school to college, marriage, parenting and 
retirement all represent important periods of time that could influence a change in 
physical activity38, 40. Available studies examining changes in LTPA have shown that 
increased physical activity in middle age can increase longevity after an induction period 
of up to 10 years23, 24. In men younger than 70 years, increases or negligible declines in 
total and high-intensity LTPA are associated with lower risk for all-cause mortality 
compared to greater declines in LTPA39. Changes from a sedentary to an active physical 
activity pattern, even if initiated at older age, also may result in a strong reduction in risk 
for a primary CVE41, 42. Despite the established protective effect of physical activity for 
the primary prevention of CHD16, 43, the association between life-course physical activity 
and the onset of primary and secondary CVEs has been poorly examined, with conflicting 
results41, 44-47. In patients with CHD the reported levels of LTPA could reflect 
longstanding patterns of exercise as well as changes in physical activity since the 
  
10 
diagnosis of CHD13. The association between life-course trajectories of physical activity 
and recurrent CVEs has not been examined.  
 
This dissertation will examine the association between LTPA practice reported at 
one year after an initial CVE as well as the LTPA-trajectories for the age-period 20-49 
years and the onset of a secondary CVE in patients with stable CHD. These patients 
participated in a three-week inpatient cardiac rehabilitation program after the onset of an 
acute coronary event. In Study 1 of LTPA one year after a CVE, we hypothesize that, 
compared to stable cardiac patients reporting LPTA of 2-4 times/week at one year post 
event, those who report LTPA 5-6 times/week will have a reduced risk, and those 
reporting LTPA less than 2-4 times/week will have an increased risk of a secondary 
CVE.  In Study 2 of LTPA trajectories, we hypothesize that among stable cardiac patients 
50-69 years of age at baseline those reporting sustained high LTPA levels during the age 
periods 20-29, 30-39, and 40-49 years will have the lowest risk, and those reporting 
sustained low levels of LTPA for the given age periods will have the highest risk for a 
secondary CVE, compared to the reference group of patients reporting a gradual decline 
of LTPA over time.  These findings could improve our understanding of LTPA 
trajectories and inform the development of programs oriented to maximize the life-long 
implementation of guidelines for physical activity40, 48. 
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STUDY 1 - PHYSICAL ACTIVITY AFTER ONE YEAR OF 
CARDIAC REHABILITATION AND THE ONSET OF A 
SECONDARY CARDIOVASCULAR EVENT 
 
METHODS 
Study Sample 
This study used the KAROLA cohort described on page 4. In addition to the 
inclusion/exclusion criteria already described, this study had the following exclusion 
criteria: time of follow-up less than 365 days (n=260); secondary CVE within the first 
year of follow-up (n=41); missing values for LTPA at one-year follow-up (n=10). Thus, a 
total of 891 participants remained for this analysis. 
 
Definition of Variables 
Leisure Time Physical Activity.  
Participants were asked in the one-year follow-up questionnaire how often on 
average (daily, 5-6 times/week, 2-4 times/week, once a week, 1-3 times/month, 
seldom/never) they practiced strenuous LTPA that caused them to sweat (for example 
bike, rapid walk, gardening, sport) during the previous 12 months. LTPA was 
operationalized by building the following four categories: at least 5-6 times/week, 2-4 
times/week, 1-4 times/month and seldom/never (Figure 2). 
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In the Questionnaire For Analysis 
Daily 
At least 5-6 times/week 
5-6 times/week 
2-4 times/week 2-4 times/week 
Once a week 
1-4 times/month 
1-3 times/month 
Seldom/never Seldom/never 
 
Figure 2. Operationalization of the variable leisure time physical activity. 
 
Covariates 
Covariate data were collected from the questionnaires at baseline (sex, level of 
education, status post MI, and status post CABG) and at one-year follow-up (age, 
smoking status, alcohol consumption in the previous 12 months, BMI, history of 
hypertension, history of diabetes, history of heart failure, self-assessed health status, and 
current use of medications: aspirin, ACE inhibitors, beta-blockers, calcium-antagonists, 
diuretics or statins).  
 
Blood parameters 
 Baseline fasting blood samples were obtained at the end of the rehabilitation 
program (baseline values). Serum samples were brought within two hours to the 
laboratory for further processing. Samples were stored for up to one month at -20°C and 
then transferred on dry ice to a -80°C freezer until analysis. Serum NT-proBNP was 
measured at baseline using a one-step enzyme immunoassay based on 
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electrochemiluminescence (Roche Elecsys 2010; Roche Diagnostics, Mannheim, 
Germany, interassay coefficient of variation 3-7%).  
 
Statistical Analysis 
Descriptive analyses were conducted to assess the proportions of individuals 
within each category of LTPA and potential confounders. Discrete variables are 
presented as counts and percentages, and continuous variables as arithmetic means and 
standard deviations or medians and/or quartiles based on their distribution, for the study 
population as well as stratified by LTPA. The rates of secondary CVEs with their 
respective 95% confidence intervals (CI) are reported for each category of LTPA.  
 
We evaluated the association between levels of LTPA and each variable identified 
as a possible confounder with the onset of a secondary CVE using a Cox-proportional 
hazards model, with follow-up beginning at the corresponding date for the one-year 
follow-up, for a maximum length of nine years of follow-up (Figure 3). Those subjects 
reporting a 2–4 times/week LTPA practice served as the reference group. We evaluated 
collinearity among the potential confounders of interest. A backward deletion strategy 
was used to select confounders from the full Cox-proportional hazards model including 
the following covariates identified as possible confounders: BMI, smoking, alcohol 
consumption, level of education, natural log-transformed (ln) NT-proBNP, history of 
hypertension, history of diabetes, history of heart failure, status post myocardial 
infarction, status post CABG, use of aspirin, ACE inhibitors, beta-blockers, calcium-
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antagonists, diuretics and statins. Confounding was assessed based on whether removal 
of the potential confounder generated a change of greater than 10% in the parameter 
estimate of LTPA category. The assumption of proportional hazards was checked by 
including time-dependent interactions of each variable with the natural logarithm of 
survival time. We detected a violation of the proportional hazard for the confounder use 
of diuretics; thus, the Cox-proportional hazards models were performed using use of 
diuretics as strata. From the multivariable analysis the hazard ratio (HR) and 
corresponding 95% CI are provided for the association between each level of LTPA 
practice at one-year follow-up and the onset of a secondary CVE, compared to the 
reference group. We considered two-sided p<0.05 as indicating statistical significance. 
All analyses were performed using SAS software, version 9.2 (SAS Institute Inc., Cary, 
North Carolina). 
 
We performed several secondary analyses. Knowing that the presentation of 
CVDs and their associated risk vary by sex49, 50, we examined the relationship of LTPA 
with a secondary CVE among men; there were too few women to analyze separately. We 
were concerned with the possible effect of reverse causation, such that the reported level 
of LTPA might be directly associated with a diminished health status due, for example, to 
comorbidities. As a result, the obtained hazards might reflect in part the effect of other 
causes for diminished health status and not the effect of LTPA. To evaluate this 
possibility, an analysis excluding those who reported a poor health status at baseline also 
was performed. Self-assessed health status is a well validated measure of how an 
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individual perceives his or her health51.  
 
 
 
 
 
 
 
 
Figure 3. Study design for the assessment of leisure time physical activity at one-year 
follow-up. 
 
RESULTS 
Table 1 shows the characteristics of the study population (n=891) at one-year 
follow-up. The mean age was 60.2 ± 7.9 years, with a male participation equal to 85.3%. 
A total of 52.5% of the subjects were overweight, and 20.2% obese. About 56.7% 
reported moderate alcohol consumption, while only 18.7% reported high alcohol 
consumption. Current smoking was reported by 7.9%. History of diabetes was present 
among 16.6%, and history of heart failure among 12.9% of the participants.  
 
 
 
Level of 
LTPA 
Start cardiac 
rehabilitation 
End cardiac 
rehabilitation 
(Baseline) 
1 year 
follow-up 
10 years 
follow-up 
// 
9 years follow-up 
  
16 
Leisure Time Physical Activity 
As noted in Table 2, at one-year follow-up only 7.6% reported seldom/never 
LTPA practice, while 17.7, 42.6 and 32.0% reported LTPA 1-4 times/month, 2-4 
times/week and at least 5-6 times/week, respectively. Those in the reference group of 
LTPA 2-4 times/week were younger (59.2 ± 8.1 years), while those reporting a LTPA 
practice of 5-6 times/week were older (61.3 ± 7.3 years).  Those subjects reporting 
seldom/never LTPA practice had a higher prevalence of females, and a higher proportion 
reporting lower levels of alcohol consumption, current smoking, history of hypertension, 
history of diabetes, history of heart failure, and use of diuretics. They also had higher 
baseline levels of NT-proBNP and a lower prevalence of subjects taking beta-blockers 
and statins. 
 
We observed a total of 104 secondary CVEs during follow-up (median follow-up 
8.9 years (interquartile range [7.0, 9.0]), representing an incidence rate (IR) equal to 15.2 
secondary CVEs per 1000 person-years [95% CI 12.5, 18.3]. The IR was the highest 
among those with seldom/never levels of LTPA (24.5 secondary CVEs per 1000 person-
years [95% CI 13.0, 42.4]), and the lowest among those practicing at least 5-6 times/week 
LTPA at one year follow-up (13.7 secondary CVEs per 1000 person-years [95% CI 9.5, 
19.2]) (Table 3). We did not detect a statistically significant difference among the 
survival curves for the different LTPA levels (Log-rank test p-value 0.267) (Figure 4). 
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Crude Analysis 
In the crude analysis, those reporting seldom/never levels of LTPA had 1.81 times 
the hazard of suffering a secondary CVE [95% CI 0.93, 3.52], while those reporting 
LTPA 1-4 times/month had a HR of 1.27 [95% CI 0.75, 2.15], compared to those 
reporting LTPA 2-4 times/week. Participants with the highest level of LTPA practice had 
a HR of 0.99 [95% CI 0.62, 1.57]. Age, NT-proBNP levels at baseline, and the use of 
diuretics were statistically significant associated with the onset of a secondary CVE 
(Table 4). 
 
Multivariable Analysis 
After adjustment for age and sex those subjects reporting the lowest levels of 
LTPA (seldom/never) had 1.93 times the hazard to suffer a secondary CVE [95% CI 
0.95, 3.92], while those reporting 1-4 times/month had a HR of 1.22 [95% CI 0.70, 2.14] 
with respect to our reference group. A HR of 0.98 [95% CI 0.60, 1.58] was observed for 
those reporting LTPA at least 5-6 times/week. In the multivariable analysis (n=819, 97 
CVEs) adjusting for baseline levels of ln NT-proBNP, current smoking, alcohol 
consumption, history of hypertension, history of diabetes, history of heart failure, level of 
education, status post CABG, and use of aspirin, ACE inhibitors, beta-blockers, calcium 
antagonists and diuretics, the associations between seldom/never and 1-4 times/month 
LTPA practice and the onset of a secondary CVE were attenuated with HRs of 1.30 [95% 
CI 0.62, 2.69] and 0.98 [95% CI 0.54, 1.75], respectively. At the same time, we observed 
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a strengthening of the reduction in risk among those reporting LTPA at least 5-6 
times/week LTPA with a HR of 0.88 [95% CI 0.54, 1.43] (Table 5).  
 
The results were similar when restricting the analysis to men (Appendix 1). When 
evaluating the presence of reverse causation by restricting the sample to those reporting 
regular or good health status, we observed an attenuation of the HR for those reporting 
seldom/never practice of LTPA, as well as an increased risk protection for those reporting 
1-4 times/month. No change in the hazard could be seen among those reporting the 
highest level of LTPA (Appendix 2). These findings suggest that the initially observed 
increased hazard was probably not only related to a seldom/never practice of LTPA, but 
also to the presence of a poor health condition which might lead to a limited practice of 
physical activities. In the same way, the potential protective effect of an LTPA of 1-4 
times/week may have been underestimated. 
 
DISCUSSION 
The present study shows that a low level of LTPA practice reported one year after 
an initial CVE is associated with an increased risk for a secondary event. In addition, our 
data support the protective effect of physical activity in patients with stable coronary 
heart disease among subjects who survived the first year after an acute coronary event, 
where the highest levels of LTPA were associated with a reduction in risk, even after 
adjustment for identified confounders including established cardiovascular risk factors. 
Similar results were observed when the analyses were restricted to men.  
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The prevalence of subjects reporting at least 5-6 times/week and 2-4 times/week 
of LTPA observed in our study sample are much higher than the reported proportion of 
16% among US adult subjects (18-74 years) participating in light and moderate physical 
activity for 30 min per day for greater than seven times a week52 or the described 
proportion in Germany of 17% of adult men and 9% of adult women practicing 30 min of 
physical activity at least three days a week53. Such a difference could be related to 
different factors. Perhaps individuals who seldom exerted physical activity did not 
survive the initial CVE, while those who were more physical active did survive. In 
addition, patients with stable coronary heart disease participating in a cardiac 
rehabilitation program may be better informed and more conscious about the benefits of 
physical activity than the general population. These results may also reflect in part the 
effect of social desirability, defined as the defensive tendency of individuals to portray 
themselves in keeping with perceived cultural norms54. The prevalence of 7.7% for 
subjects reporting seldom/never LTPA practice also is markedly lower compared to the 
25% reported for the general US population52, 55, and to the 53% reported for the general 
German population56. 
 
Although it has been reported that older adults are less likely to meet general 
recommendations of LTPA57, in our sample those reporting the highest level of LTPA 
were the oldest. In addition, those individuals reporting the lowest level of LTPA 
(seldom/never) had a higher proportion of subjects with severe depression of LV function 
at baseline, comorbidities (such as hypertension, diabetes, heart failure), use of diuretics, 
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as a marker for decreased ventricular function, as well as a lower prevalence for low 
alcohol consumption. Overall, the least active subjects were markedly different and 
perhaps sicker than the subjects included in the other three LTPA groups. As expected, 
our analysis evaluating the presence of reverse causation indicated a potential bias of the 
observed estimates. After exclusion of those reporting poor health status at one-year 
follow-up, the hazard ratios were attenuated for those with lower levels of LTPA, and the 
highest level of LTPA was not associated with a reduction in risk (Appendix 2). 
 
Low or moderate vigorous physical activity has been shown to lower the risk for 
cardiovascular mortality in the general population, adjusting for metabolic risk factors58. 
With respect to total mortality within the prospective population-based Nord-Trøndelag 
Health Study (HUNT), the largest benefit was reported among those who increased their 
levels of LTPA from no exercise to just a little 22, 59. Regular practice of exercise of 
moderate intensity has been associated with reduced platelet aggregability60, and 
increased vagal tone. In patients with ischemic CHD, regular physical activity can 
increase maximal physical performance and lift the ischemia threshold for a given work 
load61. In this context, a study including men with CHD in the British Heart Study 
showed a significant reduction in risk of total and cardiovascular mortality among those 
reporting light and moderate levels of physical activity compared to those who were 
inactive, even after adjustment for age, social class, smoking, obesity, history of MI, 
diabetes, stroke, and self-rated health status. The authors concluded that vigorous or 
“sporting” activity is not required and regular leisure activities such as walking and 
  
21 
gardening appear to be sufficient to achieve significant benefits’21. A study including 
survivors of a first MI showed that those who remained active during the five annual 
follow-ups had a 60% lower risk of fatal or nonfatal re-infarction than those who 
remained sedentary, with a further reduction of the risk to 78% among those who 
increased their activity after the first MI during this period of time20. A recent statement 
of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) 
states that in CHD patients with stable angina pectoris, treatment including medication 
and regular exercise training can be considered equivalent or even superior to medication 
and elective interventional strategies with respect to exercise capacity, myocardial 
perfusion, and clinical events62. 
 
Limitations 
Our study consisted mostly of men of European ancestry. We were not able to 
evaluate the association of levels of LTPA at one-year follow-up and subsequent events 
among women. This is especially relevant since physical inactivity is known to be more 
prevalent among women than their male counterparts63. The modest sample size led to 
wide confidence intervals around the observed effect estimates. We also were not able to 
examine the association between levels of LTPA at one-year follow-up with each of the 
single adverse events -- fatal myocardial infarction, fatal stroke, non-fatal myocardial 
infarction, and non-fatal stroke -- due to the low number of events in each group. In 
addition, our study was based on the assessment of LTPA at one-year follow-up. We 
lacked information about changes of level of LTPA during the nine-year follow-up and 
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their association with subsequent CVEs. At the same time, the definition of physical 
activity was based on the question “How often on average did you practice strenuous 
LTPA that caused you to sweat (for example bike, rapid walk, gardening, sport) during 
the previous 12 months”, which may not be precise enough. This, in addition to the lack 
of information with respect to duration, could have resulted in an inaccurate 
categorization of LTPA with respect to the intensity of physical activity practice. It is 
also possible that we have misclassification of the subjects across the LTPA-groups. 
However, the information regarding LTPA was collected prior to the occurrence of the 
secondary CVE so that, if present, the misclassification of the exposure would be most 
likely non-differential with respect to the outcome. Last, not all patients may participate 
in cardiac rehabilitation, and we could be missing the most severe cases in our cohort64, 
affecting not only the generalizability of the results. The possibility of selection bias also 
exists if such patients did not participate in the cardiac rehabilitation due to their level of 
LTPA. 
 
Conclusion 
Our data support the protective effect of physical activity in patients with stable 
coronary heart disease even among subjects who survived the first year of follow-up after 
an acute coronary event. As stated in our hypothesis, self-reported increased levels of 
LTPA (5-6 times/week) at one-year follow-up showed a decreased hazard, while those 
subjects with seldom/never practice of LTPA at one-year follow-up had a higher hazard 
for the onset of a secondary CVE. Knowing the limitations of self-report of physical 
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activity, it would be of interest to evaluate the effect of LTPA with respect to the 
subsequent events in this population using movement monitors such as accelerometers. 
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Table 1. KAROLA cohort study population characteristics at one-year follow-up. 
Study sample, n 891 
Age (years), mean ± SD 60.2±7.9 
Male, n (%) 760 (85.3) 
BMI (kg/m
2
), mean ± SD 27.6±3.8 
BMI categories, n (%)   
Normal weight  243 (27.3) 
Overweight  468 (52.5) 
Obese  180 (20.2) 
Smoking, n (%)   
Current smoker  70 (7.9) 
Alcohol consumption, n (%)   
Low  (less than 14 g/week)  219 (24.6) 
Moderate (≤ 196 g/week for male, ≤ 98 g/week for female)  505 (56.7) 
Heavy (> 196 g/week for male, > 98 g/week for female)  167 (18.7) 
Education, n (%)  
≤ 9 years 717 (81.0) 
> 9 years 168 (19.0) 
NT-proBNP (pg/ml), median (Q1, Q3) 546.1 (281.4, 1077.0) 
History of Hypertension, n (%)  512 (57.5) 
History of Diabetes, n (%)  148 (16.6) 
History of Heart Failure, n (%)  115 (12.9) 
Status post Myocardial Infarction, n (%) 454 (50.9) 
Status post CABG, n (%) 435 (48.8) 
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Table 1 (cont.). KAROLA cohort study population characteristics at one-year follow-
up. 
Medications, n (%)   
Aspirin  721 (84.9) 
ACE inhibitors 459 (54.1) 
Beta-blockers 696 (82.0) 
Calcium antagonists 98 (11.5) 
Diuretics  212 (25.0) 
Statins  647 (76.2) 
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Table 4. Crude analysis. 
 
 HR 95% CI 
Levels of LTPA at one-year follow-up 
Seldom/never  1.81 [0.93, 3.52] 
1-4 times/month  1.27 [0.75, 2.15] 
2-4 times/week 1.00  
At least 5-6 times/week 0.99 [0.62, 1.57] 
Age 1.03 [1.00, 1.06] 
Sex (male reference) 0.54 [0.27, 1.06] 
BMI (kg/m2) 1.00 [0.95, 1.06] 
BMI (categorical)   
Normal (Ref) 1.00  
Overweight 0.67 [0.42, 1.07] 
Obese 0.90 [0.51, 1.56] 
Current smoking 1.63 [0.89, 2.97] 
Alcohol consumption   
Low  1.14 [0.71, 1.84] 
Moderate (Ref)  1.00  
Heavy  1.54 [0.96, 2.46] 
Education   
≤ 9 years (Ref)  1.00  
> 9 years  1.34 [0.85, 2.12] 
Ln NT-proBNP 1.53 [1.27, 1.83] 
History of Hypertension  1.48 [0.98, 2.21] 
History of Diabetes  1.22 [0.74, 2.01] 
History of Heart Failure  1.37 [0.80, 2.34] 
Status post Myocardial Infarction  1.00 [0.68, 1.48] 
Status post Coronary Artery Bypass Graft  1.00 [0.68, 1.47] 
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Table 4 (cont.). Crude analysis. 
 
 HR 95% CI 
Medications at one-year follow-up   
Use of ACE Inhibitors  1.08 [0.73, 1.60] 
Use of Aspirin  0.64 [0.40,1.03] 
Use of Beta-Blockers 1.20 [0.69, 2.08] 
Use of Calcium antagonist 0.94 [0.50, 1.77] 
Use of Diuretics 1.90 [1.27, 2.86] 
Use of Statins  0.84 [0.54, 1.32] 
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Table 5. Cox-proportional hazards models evaluating the association between LTPA at 
one-year follow-up and a subsequent CVE. 
 
 
Adjusted for age and 
sex 
Multivariable Model* 
 
HR 95% CI HR 95% CI 
Seldom/never  1.93 [0.95, 3.92] 1.30 [0.62, 2.69] 
1-4 times/month  1.22 [0.70, 2.14] 0.98 [0.54, 1.75] 
2-4 times/week (Ref) 1.00  1.00  
At least 5-6 times/week  0.98 [0.60, 1.58] 0.88 [0.54, 1.43] 
* adjusted for age, sex, ln NT-proBNP, BMI, current smoking, alcohol consumption, 
history of hypertension, history of heart failure, history of diabetes, level of education, 
status post CABG, use of aspirin, ACE Inhibitors, beta-blockers, calcium-antagonists 
and diuretics. 
  
 
33 
F
ig
u
re
 4
 
                   
 
F
o
ll
o
w
-u
p
 d
a
y
s 
0
 
5
0
0
 
1
0
0
0
 
1
5
0
0
 
2
0
0
0
 
2
5
0
0
 
3
0
0
0
 
3
5
0
0
 
P
er
so
n
s 
at
 r
is
k
 
8
9
1
 
8
7
1
 
8
4
0
 
7
8
1
 
7
2
1
 
6
9
9
 
5
9
7
 
3
6
 
 
  
34 
STUDY 2 - LIFE-LONG TRAJECTORIES OF LEISURE TIME 
PHYSICAL ACTIVITY AND THE ONSET OF A SECONDARY 
CARDIOVASCULAR EVENT 
 
METHODS 
Study Sample 
This study used the KAROLA cohort described on page 4. In addition to the 
inclusion/exclusion criteria already described, this study had the following exclusion 
criteria: age younger than 50 years (n=187) or older than 69 years (n=30) at baseline; 
censored because lost to follow-up at baseline (n=98); missing information for LTPA for 
more than two age periods (n=20) and for education (n=7). Thus, a total of 860 
participants remained for this analysis. 
 
Definition of Variables 
Leisure Time Physical Activity.  
Participants were asked at the start of cardiac rehabilitation how often (daily, 5-6 
times/week, 2-4 times/week, once a week, 1-3 times/month, seldom/never) on average 
they practiced strenuous LTPA that caused them to sweat (for example bike, rapid walk, 
gardening, sport) during the following age intervals: 20-29, 30-39, 40-49 years. Reported 
level of LTPA was collected from the baseline questionnaire and operationalized for each 
age period as described on page 11.  
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Covariates.  
Covariate data at baseline were collected for age, sex, level of education, 
smoking, and alcohol consumption.  
 
Statistical Analysis 
Descriptive analyses were conducted to assess the proportions of individuals 
within each LTPA category for each age period and for the collected covariates. The 
individual trajectories for reported level of LTPA across the age periods (20-49 years) 
were evaluated. By fitting a semi-parametric mixture model to the individual data 
(PROC TRAJ in SAS), five subgroups were identified as the optimum number to be 
used for further analysis 65. Figure 5 illustrates the obtained groups of LTPA 
trajectories. Those reporting a performance of seldom/never in all corresponding age 
periods were defined as participants with sustained low levels of LTPA or Trajectory 1 
(red line in Figure 5). Those reporting a performance of at least 5-6 times/week of LTPA 
in all corresponding age periods were defined as participants with sustained high levels 
of LTPA or Trajectory 5 (yellow line in Figure 5). The reference group, or Trajectory 4, 
included those subjects showing a gradual decline of LTPA levels over time (black line 
in Figure 5). Two other groups were identified: those having a steeper decline of LTPA 
over time or Trajectory 3 (blue line in Figure 5), and those showing a continuous 
increase in the level of LTPA over time or Trajectory 2 (green line in Figure 5).  
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Figure 5. Trajectories of leisure time physical activity 
 
The rate of secondary CVEs and its 95% CI are reported for each trajectory 
group. Discrete variables are presented as counts and percentages, and continuous 
variables as arithmetic means and standard deviations or medians and/or quartiles based 
on their distribution, for the study population as well as stratified by trajectories of 
LTPA. The obtained trajectory groups were incorporated as a categorical variable in a 
Cox-proportional hazards model with new onset of a secondary CVE as the outcome of 
interest. Follow-up began at the end of the in-patient cardiac rehabilitation, for a 
maximal length of ten years (Figure 6). Adjustment was performed for age, sex, level of 
education, smoking, and alcohol consumption, all variables identified as confounders of 
this association. The assumption of proportional hazards was checked by including time-
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dependent interactions of each variable with the natural logarithm of survival time.  We 
detected a violation of the proportional hazard for the confounder sex, so that Cox-
proportional hazards models were performed in SAS using sex as strata. The final 
multivariable model provided the HRs and corresponding 95% CIs for the association 
between the obtained groups of LTPA trajectories across the age periods prior to the 
initial event and the onset of a secondary CVE. We considered two-sided p<0.05 as 
indicating statistical significance. All analyses were performed using SAS software, 
version 9.2 (SAS Institute Inc., Cary, North Carolina). 
 
Since the presentation of CVDs and their associated risk vary across the 
sexes49,50, we examined this association among men in a secondary analysis; there were 
too few women to analyze them separately.  In order to evaluate the presence of reverse 
causation on more recent LTPA, as in Study 1, we performed an additional analysis 
restricting our sample to those reporting a regular or good health status at baseline.  
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Figure 6. Study design for the assessment for the LTPA trajectories during the age 
period 20-49 years. 
 
RESULTS 
Table 6 shows the characteristics of the study population (n=860) at baseline. The 
mean age was 61.2 ± 5.0 years, with a male participation equal to 84.3%. About 47.9% 
reported moderate alcohol consumption, while only 21.5% reported high alcohol 
consumption. Only 4.1% reported current smoking at baseline. Our study sample had a 
mean BMI equal to 27.0 ± 3.4 kg/m2. History of diabetes was present among 18.1%, and 
history of heart failure among 12.3% of the participants.  
 
Trajectories of Leisure Time Physical Activity 
When looking at the levels of LTPA reported for each age period, we observed a 
continuous decline in the prevalence of those practicing LTPA at least 5-6 times/week 
from 24.1% at the age period 20-29, to 15.1% for the age period 40-49. There was a 
LTPA 
Trajectories 
End cardiac 
rehabilitation 
(Baseline) 
10 years 
follow-up 
// 
10 years follow-up 
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continuous increase in the proportion of those who practiced LTPA 1-4 times/month from 
24.4% to 37.3% across the three age periods. The proportion of subjects practicing LTPA 
seldom/never or 2-4 times/week was stable over time with an average prevalence of 
15.2% and 33.5%, respectively (Table 7, Figure 7). 
 
We observed that 13.8% of the study participants were included in Trajectory 1 of 
those with low levels of LTPA for all age periods, while 15.7% of subjects were 
categorized in Trajectory 5 of those with high levels of LTPA for all age periods. 
Trajectory 2, which included those with a gradual increase of LTPA over time, 
represented 25.0% of the study sample.  A steeper decrease of LTPA over time was 
observed among those in Trajectory 3 and represented 15.3% of the study sample. Our 
reference group Trajectory 4, which included those with a gradual decline of LTPA over 
time, was 30.1% of the study sample.   
 
Table 8 summarizes the participant characteristics stratified by the estimated 
trajectories of LTPA. We noted that those with a continuous increase of LTPA over time 
(Trajectory 2) were the youngest (60.5 ± 4.9 years), while those with a high level of 
LTPA over time (Trajectory 5) were the oldest (62.1 ± 4.5 years). For those in Trajectory 
1, we observed the highest prevalence of women, the highest mean BMI, and the highest 
proportions reporting low levels of alcohol consumption and a history of diabetes.  
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We observed a total of 125 secondary CVEs during follow-up (median follow-up 
was 9.9 years (interquartile range [6.0, 10.0]), representing an IR equal to 18.9 secondary 
CVEs per 1000 person-years [95% CI 15.8, 22.4]. The IR was highest among those in 
Trajectory 3 (28.4 secondary CVEs per 1000 person-years [95% CI 19.3, 40.4]), and 
lowest for those in Trajectory 2 (12.1 secondary CVEs per 1000 person-years [95% CI 
7.7, 18.2]) (Table 9). The survival curves for the LTPA trajectories were significantly 
different (Log-rank test p-value 0.043) (Figure 8). 
 
Crude Analysis 
The highest hazard for the onset of a secondary CVE was seen among those in 
Trajectory 3, representing subjects with a steeper decline of LTPA over time, while those 
showing a continuous increase in the level of LTPA (Trajectory 2) had the lowest hazard 
(HR 1.62 [95% CI 0.99, 2.66] versus HR 0.70 [95% CI 0.41, 1.19]). Those participants in 
Trajectory 1 representing subjects with low levels of LTPA over time had a HR of 1.21 
[95% CI 0.69, 2.14]. Those reporting the highest level of LTPA over time had a HR of 
1.27 [95% CI 0.75, 2.15] with respect to the onset of a secondary CVE. We also observed 
that those with a history of diabetes were statistically significant associated with the onset 
of a secondary CVE (Table 10). 
 
Multivariable Analysis 
The highest risk for a secondary CVE was observed among those in Trajectory 3 
of subjects with a steeper decrease of LTPA over time after adjustment for age, sex, 
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smoking, education and alcohol consumption with a HR 1.59 [95% CI 0.97, 2.62]. An 
increased hazard for a secondary CVE was also observed among those in Trajectory 1, 
the least active, (HR 1.31 [95% CI 0.74, 2.32]), as well as among those in Trajectory 5, 
the most active, (HR 1.31 [95% CI 0.77, 2.23]). The increase in LTPA over time 
represented in Trajectory 2 was associated with a protective effect (HR 0.71, [95% CI 
0.41, 1.22]) (Table 11). The results were similar when restricted to men (Appendix 3).  
 
When restricting the sample to those reporting regular or good health status, we 
still observed an increased risk for a secondary CVE among those reporting the lowest 
and the highest level of LTPA over time with HR 1.15 [95% CI 0.61, 2.17] and 1.28 
[95% CI 0.72, 2.26], respectively. Having a steeper decrease of LTPA over time was 
associated with an increased risk (HR 1.66 [95% CI 0.98, 2.81]), while having a 
continuous increase of LTPA over time was still associated with a risk reduction (HR 
0.71 [95% CI 0.40, 1.26] (Appendix 4). 
 
 DISCUSSION 
Our study showed a decline in the prevalence of those practicing LTPA at least 5-
6 times/week and a simultaneous increase of those practicing 1-4times/month over the 
age period 20-49 years among patients with stable coronary heart disease. Contrary to our 
hypothesis we observed the highest hazard for a secondary CVE among those subjects 
with a steeper decrease of LTPA during the age period 20-49 years, followed by those 
with either sustained low or sustained high practice of LTPA over that age period. 
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Having a continuous increase of LTPA during this age period showed a strong risk 
reduction for the onset of a secondary CVE. 
 
The observed mean prevalence of 15.2% for those reporting seldom/never LTPA 
practice over time is markedly lower compared to a prevalence of 25.0% reported in the 
US general population52, 55, as well as to the 53.0% reported for the general German 
population56. The observed decline in LTPA practice over time among those reporting 5-
6 times/week has been described and could be explained by the fact that with increasing 
age adults spend less of their discretionary time in the practice of LTPA66.  The high 
proportion of women observed among those with sustained low levels of LTPA is 
consistent with data coming from the US population that show that women are less likely 
to participate in sports and exercise when compared to men in the same age67, 68. 
According to the US Center for Disease Control and Prevention, only 42.6% of women in 
contrast to 52.1% of men meet the 2008 Physical Activity Guideline for aerobic 
activity69. However, data arising from the German population showed in the last decade a 
higher proportion of women practicing physical activity at least once a week when 
compared to men across the age periods 40-54 and 55-69 with a 67.7 versus 65.1% and a 
65.7 versus 58.4% prevalence, respectively. With respect to the recommendation of 
practicing 30 minutes of physical activity at least three days a week in Germany, 17% of 
adult men versus only 9% of adult women follow this recommendation53. 
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Among those subjects reporting sustained low levels of LTPA (Trajectory 1), we 
observed the highest average BMI, a higher proportion of individuals with diabetes, as 
well as the highest proportion of subjects reporting low alcohol consumption. Overall the 
subjects in this group were different from the rest of the sample, and perhaps sicker than 
the subjects included in the other four trajectories. These observations are in accordance 
with research studies suggesting that health, rather than age, social status, or other related 
psychosocial factors, is the most important determinant of patterns of LTPA among 
adults70, 71. In such a setting, the presence of a bias due to reverse causation should be 
considered. In order to evaluate this, we performed a sensitivity analysis excluding those 
subjects who reported a poor health status at baseline. We observed an attenuation to the 
null of the estimated hazard ratio for those in Trajectory 1, although still indicating an 
increased hazard for the onset of a secondary CVE (Appendix 5). 
 
We observed a higher proportion of subjects with education ≤ 9 years among 
those reporting a sustained low or high level of LTPA (Trajectories 1 and 5). The highest 
proportion of subjects with > 9 years of education was observed among those having a 
continuous increase in the level of LTPA over time (Trajectory 2). This last observation 
is consistent with reports that those with higher levels of education have higher levels of 
participation in sport and exercise in adulthood, driven perhaps by the presence of parents 
with more resources, parents who themselves participated in sport, better social and 
environmental support for the practice of physical activity, and, last, a better 
understanding of the benefits of sports and exercise48, 72. 
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The estimated risk reduction for the onset of a secondary CVE among those 
having a continuous increase of LTPA during the age period 20-49 is consistent with the 
results of diverse studies showing that an increase in physical activity can lead to a 
reduction in cardiovascular mortality, as well as cardiovascular risk factors73. Among 
women in the Nurses’ Health Study, those subjects who became active in middle age had 
a lower risk for the onset of a CVE when compared to their sedentary counterpart74. The 
initiation of moderately vigorous activity has been  associated with a lower risk for 
cardiovascular death among middle-aged and older men75. Increased levels of LTPA in 
middle age also have been associated with an increase in longevity after an induction 
period of up to 10 years of no benefit. In analogy a continuous decreased of LTPA over 
time have been associated with higher mortality rates23. Any increase of LTPA correlates 
with an improvement in the individual metabolic profile, which includes decreases in 
BMI, glucose and lipids76, as well as with changes in inflammatory response77. 
 
Limitations  
The results of our analysis were based on the self-report of levels of physical 
activity performed during the age period 20-49 years, leading to possible recall error. 
Data are more accurate when the recall period is shorter, the activity being measured is 
salient, and the behavior studied is habitual over a long period of time48. In this respect, 
the LTPA trajectories 1 to 4 were associated in the expected directions with other 
participant characteristics such as BMI. Our study consisted mostly of men of European 
ancestry so that we were not able to evaluate the association of LTPA trajectories and the 
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subsequent events among women. This is especially relevant since physical inactivity is 
known to be more prevalent among women than their male counterparts63. We also were 
not able to examine the association between LTPA trajectories with specific adverse 
events such as fatal myocardial infarction, fatal stroke, non-fatal myocardial infarction, 
and non-fatal stroke, due to the low number of events in each group. In addition, not all 
cardiac patients may participate in cardiac rehabilitation, so that we could be missing the 
most severe cases in our cohort64, affecting the generalizability of the results. 
 
Contrary to our hypothesis, we observed a higher risk among those reporting 
sustained high levels of LTPA (Trajectory 5). This could be related to the presence of 
misclassification. The definition of the trajectories was not only based on self-report for 
the age period 20-49, but also lacked of information about the duration of practice of 
LTPA. The available literature shows a correlation between objective measures of LTPA 
and self-reported LTPA instruments from 0.22 to 0.4978. Therefore, using relatively 
imprecise measures of physical activity is likely to have biased the estimates of 
associations16, 38. Social desirability, defined as the defensive tendency of individuals to 
portray themselves in keeping with perceived cultural norms54, could also lead to a 
misclassification of the subjects into the categories with higher levels of LTPA practice79, 
which could explain the fact that we observed the highest mean age in this group, the 
second highest mean BMI, as well as the highest proportion of subjects with history of 
heart failure. However, since the information regarding previous practice of LTPA was 
collected prior to the occurrence of the secondary event, this would lead to a non-
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differential misclassification of the exposure. Last, information on smoking and alcohol 
consumption were collected at baseline and therefore could have been influenced by the 
prior practice of LTPA. In such a scenario they would be considered to be in the causal 
pathway as mediators rather than confounders of the observed associations.   
 
Conclusion 
As postulated in the hypothesis we detected an increased hazard among those with 
sustained low levels of LTPA over time. However, high levels of LTPA were also 
associated with a higher risk for the onset of a secondary CVE, which could reflect a 
biased result due to misclassification. Changes of LTPA during the age-period 20-49 
years were associated with the onset of a secondary CVE. Patients having a steeper 
decrease of LTPA during this age period showed a higher hazard, while those having a 
continuous increase of LTPA had a reduced risk for the onset of a secondary CVE. The 
results of this study emphasize the importance to promote and support the practice of 
physical activity among adults with stable coronary heart disease. Further life-course 
cohort studies are needed assessing the levels of physical activity through questionnaires 
as well as through the use of movement devices in order to increase our understanding 
about the long-term benefits of practice of LTPA in specific areas such as the secondary 
prevention of CVD. 
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Table 6. KAROLA cohort study population characteristics at baseline. 
Sample size, n 860 
Age (years), mean±SD 61.2±5.0 
Male, n (%) 725 (84.3) 
BMI (kg/m2), mean±SD 27.0±3.4 
Smoking, n (%) 
Never smoker 305 (35.5) 
Ex-smoker 520 (60.5) 
Current smoker 35 (4.1) 
Alcohol consumption, n (%) 
Low  (less than 14 g/week) 263 (30.6) 
Moderate (≤ 196 g/week for male, ≤ 98 g/week for female) 412 (47.9) 
Heavy (> 196 g/week for male, > 98 g/week for female) 185 (21.5) 
Education, n (%) 
≤ 9 years 693 (80.6) 
> 9 years 167 (19.4) 
History of Hypertension, n (%) 513 (59.6) 
History of Diabetes, n (%) 156 (18.1) 
History of Heart failure, n (%) 106 (12.3) 
Status post Myocardial Infarction, n (%) 417 (48.5) 
Status post Coronary Artery Bypass Graft, n (%) 446 (51.9) 
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Table 7. Frequency distribution for LTPA across the different age 
periods. 
 Age period 
 
20-29 30-39 40-49 
At least 5-6 times/week 207 (24.1) 149 (17.4) 130 (15.1) 
2-4 times/week 313 (36.5) 278 (32.4) 270 (31.5) 
1-4 times/month 209 (24.4) 306 (35.7) 320 (37.3) 
Seldom/never 128 (14.9) 125 (14.6) 138 (16.1) 
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Table 10. Crude analysis. 
 HR 95% CI 
Trajectory of LTPA  
1 (sustained low level) 1.21 [0.69, 2.14] 
2 (continuous increase) 0.70 [0.41, 1.19] 
3 (steeper decline) 1.62 [0.99, 2.66] 
4 (gradual decline) 1.00  
5 (sustained high level) 1.27 [0.75, 2.15] 
Age (years) 1.02 [0.98, 1.06] 
Smoking  
Never smoker 1.00  
Ex-smoker 1.46 [0.99, 2.16] 
Current smoker 1.08 [0.38, 3.03] 
Alcohol consumption  
Low  (less than 14 g/week) 0.80 [0.52, 1.23] 
Moderate (≤ 196 g/week for male, ≤ 98 g/week for female) 1.00  
Heavy (> 196 g/week for  male, > 98 g/week for female) 1.00 [0.64, 1.56] 
Education  
≤ 9 years 1.00  
> 9 years 1.30 [0.85, 1.96] 
53 
 
 
Table 11. Cox-proportional hazards models evaluating the association 
between LTPA trajectories and the onset of a secondary CVE. 
 
Adjusted for age and 
sex 
Multivariable Model* 
Trajectories (group) HR 95% CI HR 95% CI 
1  
(sustained low level) 
1.25 [0.71, 2.21] 1.31 [0.74, 2.32] 
2  
(continuous increase) 
0.71 [0.42, 1.22] 0.71 [0.41, 1.22] 
3  
(steeper decline) 
1.63 [0.99, 2.68] 1.59 [0.97, 2.62] 
4  
(gradual decline) (ref) 
1.00   1.00  
5  
(sustained high level) 
1.26 [0.74, 2.15] 1.31 [0.77, 2.23] 
* adjusted for age, sex, smoking, education, alcohol consumption. 
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STUDY 3 - LONGITUDINAL MEASUREMENTS OF N-TERMINAL 
PRO-BRAIN NATRIURETIC PEPTIDE AND THE ONSET OF A 
SECONDARY CARDIOVASCULAR EVENT 
 
Brain Natriuretic Peptide (BNP) (active form) and N-Terminal pro-Brain 
Natriuretic Peptide (NT-proBNP) (cleavage product and inactive form80, 81) are released 
from the ventricular myocardium in the settings of volume and/or pressure overload, 
improving myocardial relaxation, and counteracting vasoconstriction, sodium retention 
and antidiuretic effects of the activated renin-angiotensin-aldosterone system80, 81. As a 
result, they are excellent markers for myocardial hemodynamic stress. They have been 
associated with different cardiac pathologies such as ischemia, atrial fibrillation, fibrosis 
and left ventricular hypertrophy82-84. Single NT-proBNP measurements have shown 
strong prognostic value for all-cause mortality or heart failure in cardiac patients83, 85-88 as 
well as in the general population89-91, providing modest improvements in risk 
discrimination after adjustment for conventional CVD risk factors92. 
 
Longitudinal changes of NT-proBNP have been examined mostly for intervals 
shorter than 12 months93-95. A decrease in NT-proBNP concentrations >30% has been 
perceived as evidence of therapeutic effectiveness in patients with chronic heart failure81, 
96. In community-dwelling older adults, NT-proBNP changes over two to three years 
were associated with changes in patient risk for a CVE adjusting for cardiovascular risk 
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factors, ejection fraction, or medication use97. Serial determinations of natriuretic 
peptides have been proposed for prognostic assessment in cardiovascular patients98. 
However, there is limited information about the within-person variability in natriuretic 
peptide levels over time92. The prognostic value of NT-proBNP among patients with 
stable CHD87, 99, whose frequency of follow-up examinations depends mainly on the 
likelihood of disease progression and the occurrence of subsequent CVEs100, is also not 
known. 
 
The following analysis evaluates the prognostic value of NT-proBNP measured 
one year after an initial CVE, compared to baseline values, as well as the association of 
longitudinal changes of NT-proBNP during the first three years after the initial event, 
related to the onset of a subsequent secondary CVE. We hypothesize that, among those 
subjects who survived the first year after the initial event, NT-proBNP levels measured at 
one-year follow-up will show better prognostic value for the onset of a secondary CVE 
compared to NT-proBNP levels measured at baseline, when added to a model including 
established prognostic factors. In addition, NT-proBNP trajectories during the first three 
years of follow-up will be associated with the onset of a secondary CVE such that the 
steeper the increase of NT-proBNP levels the higher the risk for a recurrent CVE after 
adjustment for NT-proBNP levels measured at baseline. 
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METHODS 
Study Sample 
This study used the KAROLA cohort described on page 4. In addition to the 
inclusion/exclusion criteria already described, the study had the following exclusion 
criteria: time of follow-up less than 365 days (n=301); number of affected vessels 
reported as 0 (n=11), missing values for NT-proBNP at baseline and / or at one-year 
follow-up (n=53); for LV function at baseline (n=83), for lipid profile (n=14), for 
creatinine (n=3) and for medications (n=2). Thus, a total of 735 participants remained for 
the first analysis evaluating the prognostic value of NT-proBNP measured at one year 
after cardiac rehabilitation versus baseline levels of NT-proBNP. In order to evaluate 
three-year NT-proBNP trajectories and the onset of secondary CVEs, we further excluded 
those subjects censored prior to three-years of follow-up (n=55), those who had a CVE 
between the first and the third year of follow-up (n=23), and those with missing values 
for three-years levels of NT-proBNP (n=44). A total of 613 study participants remained 
for this analysis. 
 
Definition of variables 
Covariates 
Baseline characteristics with respect to anthropometry, socio-demographic 
information, medical history, and lifestyle factors were collected from a standardized 
self-reported questionnaire administered at the beginning of the rehabilitation program.  
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Blood parameters 
 Baseline fasting blood samples were obtained at the end of the rehabilitation 
program (baseline values). Serum samples were brought within two hours to the 
laboratory for further processing. Samples were stored for up to one month at -20°C and 
then transferred on dry ice to a -80°C freezer until analysis. Blood samples at one- and 
three-years follow-up were obtained at the physician’s office, and sent per post to the 
study center laboratory for processing. Samples were then stored at -80°C until analysis. 
All marker measurements were performed in a blinded fashion. 
 
Serum creatinine 
Serum creatinine was measured by the kinetic Jaffe method (inter-assay 
coefficient of variation, CV 2.4–5.7%) in center 1 and by an enzymatic p-
aminophenazone method (inter-assay CV 1.2–2.2%) in center 2.  
 
Serum NT-proBNP 
Serum NT-proBNP was measured at baseline and at one- and three-years follow-
up using a one-step enzyme immunoassay based on electrochemiluminescence (Roche 
Elecsys 2010; Roche Diagnostics, Mannheim, Germany, interassay coefficient of 
variation 3-7%). Baseline levels of NT-proBNP were analyzed in 2003; one- and three-
years follow-up measurements were performed in 2011. The eight-year stability of NT-
proBNP was investigated by analyzing serum samples which had been stored at -80°C 
and experienced a maximum of one thaw cycle. The results measured on the testing eight 
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years ago (in 2003) were considered as Day 0 and recovery was calculated accordingly. 
The recovery was within the range of 89.5% to 103.0%. 
 
Statistical Analysis 
 Discrete variables are presented as counts and percentages, and continuous 
variables as arithmetic means and standard deviations or medians and/or quartiles based 
on their distribution. Since NT-proBNP concentration showed a skewed distribution at 
any given time point, median NT-proBNP levels across the covariates categories were 
tested using nonparametric methods (Wilcoxon signed rank sum test and Kruskal-Wallis 
test). For all analyses, the NT-proBNP levels were natural log-transformed (ln). A 
categorical variable for blood pressure was created as defined in the Framingham Risk 
Score chart for 10-year risk for CHD (Appendix 6) 101. The glomerular filtration rate 
(GFR) at baseline was estimated according to the Chronic Kidney Disease Epidemiology 
(CKD-EPI) equation102. Statistically significant differences with respect to the mean 
levels of creatinine between both rehabilitation centers were detected (center 1 mean 1.05 
± 0.41 mg/dl, center 2 mean 0.83 ± 0.2 mg/dl). Therefore, estimated GFR (eGFR) levels 
were standardized (mean 0, SD 1) for each center and pooled together for the overall 
sample. Correlations between the variables were evaluated using the partial Spearman 
correlation coefficient. 
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Assessment of prognostic value 
Using Cox-proportional hazards models we evaluated the prognostic value of ln 
NT-proBNP measured at baseline (Model 1), and at one-year follow-up (Model 2) after 
adding them to a defined prognostic model (Baseline Prognostic Model). Model 3 
examined the prognostic value of one-year ln NT-proBNP after additional adjustment for 
baseline ln NT-proBNP levels. The Baseline Prognostic Model adjusted for well-
established cardiovascular risk factors selected from the literature: age, sex, BMI, blood 
pressure, smoking, history of diabetes, total cholesterol, HDL-cholesterol, standardized 
eGFR and use of statins; because of its known association with NT-proBNP levels (ref), 
LV function also was included in the baseline model. Follow-up started at one year after 
the end of the cardiac rehabilitation, for a maximum length of nine years (Figure 9). The 
assumption of proportional hazards was checked by including time-dependent 
interactions of each variable with the natural logarithm of survival time.  
 
Based on the fact that the C-statistic is less useful with respect to evaluation of 
improvement in risk prediction of future events, and following current recommendations 
for the assessment of the improvement in the model’s predictive value, calibration using 
the Hosmer-Lemeshow chi-square statistic, the Net Reclassification Improvement (NRI) 
according to the risk strata of < 10%, 10-20%, and > 20% of predicted probability for a 
CVE103, 104, and the Integrated Discrimination Improvement (IDI) were assessed.  
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Figure 9. Study design for the assessment of the prognostic value of NT-proBNP 
 
The NRI is known to represent the sum of improvement for cases and non-cases 
when comparing the model using the variable of interest versus the model without it105. It 
depends mainly on the effect size of the new predictor rather than on the strength of the 
baseline model; its calculation focuses on the magnitude of the achieved improvement 
(0.62 for a strong, 0.40 for a medium, and 0.16 for a weak predictor), rather than on 
testing the hypothesis that improvement is greater than zero106.  
 
The IDI allows an assessment of improvement independent of chosen categories 
and is defined as the difference in discrimination slopes (Yates slopes) between the two 
models, which corresponds to the mean difference in the predicted probabilities between 
cases and non-cases107. The obtained estimate shows by how much the difference in 
average predicted probabilities between cases and non-cases can be improved when 
adding either the ln NT-proBNP at baseline (Model 1), the ln NT-proBNP levels at one-
NT-proBNP 
(model 1) 
NT-proBNP 
(model 2) 
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rehabilitation 
End cardiac 
rehabilitation 
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follow-up 
// 
  
63 
year follow-up (Model 2), or at both (Model 3) to the model with established prognostic 
factors. The 95% CIs are provided for the obtained NRIs and IDIs. Based on the fact that 
the presentation of CVDs and their associated risk vary by sex49, 50, and the small number 
of events among women, we examined in a secondary analysis the prognostic value only 
among men.  
 
Three-year NT-proBNP trajectories and the onset of secondary CVEs. 
We proceeded with joint modeling, which combined the estimation of individual 
regression lines defining each patient’s NT-proBNP trajectory from baseline to three-
years follow-up and obtaining a parameter estimate for the intercept and the slope. We 
subsequently evaluated the association between the individual NT-proBNP trajectories, 
defined by the obtained person-specific intercepts and slopes as continuous variables, and 
the onset of a secondary CVE in a Cox-proportional hazards model. Follow-up began at 
the corresponding date for the three-years follow-up exam and continued to 2010 for a 
maximum length of seven years (Figure 10). A backward deletion strategy was used to 
select confounders from the full Cox-proportional hazards model including the following 
covariates: BMI, smoking, history of diabetes, history of heart failure, LV function at 
baseline, blood pressure, standardized eGFR, total cholesterol, HDL-cholesterol, status 
post MI, status post CABG, use of diuretics and statins. Confounding was assessed based 
on whether removal of the potential confounder generated a greater than 10% change in 
the parameter estimate of the intercept and/or the slope. The assumption of proportional 
hazards was checked by including time-dependent interactions of each variable with the 
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natural logarithm of survival time. We detected a violation of the proportional hazard for 
the confounder BMI, so that the Cox-proportional hazards models were performed in 
SAS using this variable as strata. The obtained HR and its 95% CI are reported for both 
the intercept and the slope. The parameter estimate for the slope indicated the level of 
increase or decrease of the hazard for a secondary CVE for every one unit change of the 
slope of the three-years trajectory of NT-proBNP after adjustment for NT-proBNP 
baseline levels as represented by the intercept. As with the prognostic analyses, we also 
evaluated the association between the three-years trajectory of NT-proBNP and the onset 
of a secondary CVE among men. 
 
For the statistical analyses we considered two-sided p<0.05 as indicating statistical 
significance. All analyses were performed using SAS software, version 9.2 (SAS Institute 
Inc., Cary, North Carolina). 
 
 
 
 
 
 
Figure 10. Study design for the assessment of the three-years trajectory of NT-proBNP. 
// 
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RESULTS  
Prognostic value of NT-proBNP measured at one-year after cardiac rehabilitation 
versus at baseline 
 
Table 12 shows the characteristics of the 735 participants at baseline. The mean 
age was 59.2 ± 7.9 years; 84.5% of the study sample were men; 55.2% were overweight, 
and 17.1% were obese. Only 3.5% reported current smoking at baseline. History of 
diabetes was present among 16.3% of the participants. Moderate depression of the LV 
function was documented for 14.4% of the sample, and severe depression for 6%. The 
median time from primary event to blood withdrawal was 43 days, with an interquartile 
range equal to [36, 52]. The median levels for NT-proBNP were higher among females 
than males at baseline (704.1 versus 530.8 pg/mL) and at one-year follow-up (299.0 
versus 174.0 pg/mL).  
 
NT-proBNP levels at baseline and at one-year follow-up varied across the strata 
of the following covariates: age, sex, BMI, smoking, blood pressure, standardized eGFR, 
LV function, history of diabetes, and use of statins. In addition, only baseline NT-
proBNP levels were different when comparing those with status post MI versus those 
without (Table 13). 
 
During the nine-year follow-up period (median follow-up time 8.9 years 
[interquartile range 7.0, 9.0]), there were a total of 83 secondary CVEs. The IR was 14.7 
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per 1000 person-years (95% CI 11.8, 18.1). In the crude analysis, baseline and one-year 
follow-up NT-proBNP levels, BMI, blood pressure, left ventricular function, and 
standardized eGFR were associated with the onset of a secondary CVE (Table 14). 
 
After addition to the Baseline Prognostic Model, a one unit increase of ln NT-
proBNP measured one year after baseline (representing a 2.72 fold increase in NT-
proBNP levels) was associated with a higher risk for a secondary CVE (HR 1.60, [95% 
CI 1.25, 2.07]) compared to baseline levels (HR 1.35, [95% CI 1.04, 1.75]). With both 
baseline and one-year ln NT-proBNP in the same model (Model 3), baseline levels were 
markedly attenuated, while a one unit increase of one year levels of NT-proBNP was 
associated with a 63% increased risk for the onset of a secondary CVE [95% CI 1.17, 
2.27] (Table 15). 
 
Assessment of prognostic models 
When assessing model performance, we detected a statistically significant 
improvement of the model fit according to the likelihood ratio test after addition of either 
baseline ln NT-proBNP (Model 1, p-value = 0.02), one-year ln NT-proBNP (Model 2, p-
value < 0.001) or both (Model 3, p-value < 0.001). The baseline prognostic model 
showed a C-statistic equal to 0.68 (95% CI 0.62, 0.73). The observed improvements of 
the C-statistic to 0.69 (95% CI 0.63, 0.75) and 0.70 (95% CI 0.65, 0.76) were not 
statistically significant. None of the models had a good calibration according to the 
Hosmer-Lemeshow statistic (all p-value < 0.05). However, a trend towards a better fit of 
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the data after addition of either the one-year ln NT-proBNP (Model 2), or both measures 
(Model 3) could be observed. 
 
We observed an improvement in reclassification of cases and non-cases after 
addition of ln NT-proBNP levels at one-year follow-up (Model 2), as well as after 
addition of both ln NT-proBNP levels (Model 3). The addition of NT-proBNP levels at 
one-year resulted in a 13.2% reclassification of cases into a higher risk category (defined 
as net upwards reclassification) as well as a 2.1% reclassification of non-cases into lower 
risk categories (also called net downwards reclassification) for an overall statistically 
significant NRI. At the same time, having both measured levels in the model (Model 3) 
showed a net upwards reclassification of 12.0%, and a net downwards reclassification of 
24.5%. The IDI was equal to 0.012 [95% CI 0.0001, 0.024] after adding baseline ln NT-
proBNP to the Baseline Prognostic Model (Model 1). When using either the one-year ln 
NT-proBNP (Model 2), or both measures (Model 3), a three times higher IDI was 
obtained (Table 16). In secondary analyses, the results were similar for men 
(Appendices 6 and 7).  
 
Three-year NT-proBNP trajectories and the onset of secondary cardiovascular 
events. 
 
Of the 613 cohort members included in the trajectory analyses, we detected a 
pronounced decrease in median NT-proBNP levels between baseline (569.4 pg/ml) and 
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one-year follow-up (192.0 pg/ml), with a further but less pronounced decrease at three-
years follow-up (173.0 pg/ml). We observed higher levels of NT-proBNP for all three 
time points among females compared to males (Table 17). Based on the individual 
regression lines for the three-year trajectory of ln NT-proBNP, the mean value for the 
intercept was equal to 6.07 (± 1.00), while the mean value for the slope was equal to  
-0.35 (± 0.28), representing a 35% decrease, on average, of ln NT-proBNP levels for each 
one-year period. 
 
We detected an IR equal to 13.7 secondary CVEs per 1000 person-years [95% CI 
10.2, 18.1] among those with a negative slope (n=562), i.e., experiencing a decrease of 
NT-proBNP over the three-years of follow-up, versus an IR of 32.9 secondary CVEs per 
1000 person-years [95% CI 16.3, 60.1] among those with a positive slope (n=51), i.e., 
experiencing an increase of NT-proBNP over time.  
 
In the crude analysis a one unit increase of the intercept – the baseline NT-
proBNP level – was associated with a 64% increased risk for a secondary CVE (HR 1.64 
[95% CI 1.27, 2.11]). A one unit increase of the slope –the three-year trajectory of NT-
proBNP – was associated with a HR 3.67 [95% CI 1.54, 8.73]. Furthermore, a one unit 
increase of the slope was associated with a HR equal to 8.04 [95% CI 3.19, 20.26] after 
adjustment for the intercept.  
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The estimated intercept and slope were statistically significantly associated with 
the onset of a secondary CVE after adjustment for age and sex. The hazard ratios for both 
the intercept and the slope remained statistically significant after further adjustment for 
BMI, LV function, blood pressure and history of diabetes. Those subjects with a 10% 
increase in the slope, representing a 10% increase in the absolute levels of NT-proBNP 
over a three-year period, had a HR equal to 1.24 [95% CI 1.12, 1.37] for the onset of a 
secondary CVE (Table 18). In secondary analyses, the results were similar for men 
(Appendix 8). 
 
DISCUSSION 
In this cohort of patients with stable coronary heart disease, markedly elevated 
levels of baseline NT-proBNP measured at the end of the in-patient cardiac rehabilitation 
program were noted. These high levels most likely corresponded to the second peak of 
the biomarker usually registered weeks after the initial event, which may reflect the 
reversible increase in regional wall stress as a result of impaired left ventricular 
function41, 83, 98. The NT-proBNP levels at baseline tended to normalize at one-year 
follow-up, with a further decrease at three-years follow-up. 
 
The present study showed that one-year levels of NT-proBNP were independently 
associated with the occurrence of a subsequent CVE. Even after further adjustment for 
baseline levels, NT-proBNP measured one year after the initial event remained an 
important predictor of a secondary CVE, independent of LV function and other well-
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established risk factors at baseline. The addition of NT-proBNP either at baseline, at one-
year follow-up, or at both time points was associated with an improvement in the 
performance of the Baseline Prognostic Model. However, we did not detect an 
improvement in discrimination for any NT-proBNP measurement with respect to the 
Baseline Prognostic Model. Although a statistically significant difference in the predicted 
probabilities between cases and non-cases was observed in all three models, an 
improvement in reclassification with respect to the subsequent onset of a CVE was only 
achieved in the models containing one-year levels of NT-proBNP. Our data also showed 
that a three-year NT-proBNP trajectory, defined by the estimated individual regression 
lines, was associated with the onset of a secondary CVE after adjustment of the identified 
confounders. 
 
Several observational cohorts involving more than 12,000 patients have 
demonstrated that higher levels of NT-proBNP are associated with higher risk for 
mortality98. In 2006 the prognostic value of NT-proBNP with respect to subsequent 
events within 4.5 years of follow-up was examined in the KAROLA cohort and 
demonstrated the superior predictive utility of NT-proBNP when compared to C-reactive 
protein, a marker for inflammation, and creatinine clearance, a surrogate marker for 
kidney function83. In a study of patients with stable CHD in the Heart and Soul Study, 
NT-proBNP was able to predict subsequent CVEs and death, independent of traditional 
cardiac risk factors108. NT-proBNP was the only biomarker among a panel of nine 
inflammatory biomarkers able to predict secondary CVEs (both fatal and non-fatal) 
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independent of the traditional risk factors in the Heart Outcomes Prevention Evaluation 
(HOPE) study population109. Among older men with CVD but no diagnosed heart failure 
participating in the British Regional Heart Study, high levels of NT-proBNP were 
associated with major CVE, CVD mortality, major CHD events, and fatal CHD after 
adjustment for traditional cardiovascular risk factors and a statistically significant 
improvement of NRI110. In addition, Kragelund et al. demonstrated the prognostic value 
of baseline levels of NT-proBNP with respect to long-term mortality after adjustment for 
conventional cardiovascular risk factors and the degree of LV function among patients 
with stable CHD referred to the Rigshospitalet in Copenhagen for elective coronary 
angiography111.  
 
High NT-proBNP levels in asymptomatic patients could reflect subclinical levels 
of ventricular dysfunction or inducible ischemia, which may not be detectable in the 
clinic by standard measures112-114, as well as the presence of vascular dysfunction or 
atherosclerotic progression98. In a population-based study performed in Denmark, 
elevated levels of NT-proBNP were markedly and independently associated with the 
development of heart failure among subjects with normal LV function at baseline113. It 
has been shown that cardiac patients with normal NT-proBNP levels have an excellent 
prognosis irrespective of any echocardiographic findings and that NT-proBNP is able to 
discriminate between those with from those without a CVE in subjects with abnormal 
echocardiographic findings100.  
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NT-proBNP can be measured routinely using robust automated assays, making its 
use as a potential marker for a secondary CVE very attractive110. So far, follow-up 
measurements have been performed mainly in patients with heart failure. Less is known 
about the longitudinal changes of NT-proBNP levels in patients with stable CHD after a 
primary event87, 93. A randomized, placebo-controlled multicenter trial evaluating the 
efficacy of valsartan in patients with moderate to severe heart failure showed that 
changes in brain natriuretic peptide over time were associated with corresponding 
changes in subsequent mortality and morbidity. Patients with the greatest percent 
decrease in BNP at four months had the lowest mortality and event rates, and those with 
the highest percent increase had the highest event rates115. The A to Z Trial of patients 
with non-ST-elevation or ST-elevation acute coronary syndrome showed that BNP levels 
measured during the follow-up examinations were predictive of long-term clinical 
outcomes and that changes over a 12-month period were associated with survival without 
congestive heart failure99. A study within the Cardiovascular Health Study involving 
elderly subjects showed an increased risk for incident heart failure and cardiovascular 
death among those who had an increased NT-proBNP at 2-3 years follow-up, while those 
having a reduction of more than 25% over time had no difference in risk compared to 
those whose NT-proBNP levels remained low97.  
  
It has been recognized that NT-proBNP levels not only reflect the volume status 
in heart failure, but also important cardiac pathophysiologies such as left and right 
ventricular size and function, diastolic function, valvular heart disease, filling pressures, 
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heart rhythm, and even coronary ischemia. Thus, NT-proBNP levels disclose to clinicians 
the extent of an individual’s cardiac dysfunction, which comprises left and right 
ventricular size and function, diastolic function, valvular heart disease, filling pressures, 
heart rhythm, and coronary ischemia116. In addition, single NT-proBNP measurements 
have been associated with mortality and CVEs in the general population89-91 as well as in 
those with CHD83, 85-88. However, a single measurement of NT-proBNP does not reflect 
changes in clinical and subclinical disease117. In this context it has been hypothesized that 
detected changes in NT-proBNP over time may reflect changes in LV-remodeling, 
ventricular dysfunction, severity of ischemia or atherosclerotic progression by providing 
at the same time an improvement in risk stratification98, 112-116. More studies evaluating 
the association between NT-proBNP changes and functional and structural changes of the 
heart are needed in order to provide more insight into the detected association between 
changes of NT-proBNP over time and the onset of a subsequent CVE.  
 
The available data imply that among patients with a history of CHD additional 
longitudinal NT-proBNP measurements remain associated with the onset of subsequent 
CVEs and can provide additional prognostic value by helping to identify new subjects at 
very high-risk. These subjects could benefit from closer follow-up, which could allow the 
detection of changes in the existing cardiac pathophysiology as well as to optimize the 
control of their risk factors. They might also benefit from the implementation of novel 
CVD protective modalities110, such as the initiation of additional lipid related or anti-
inflammatory treatments.  
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Limitations  
A potential limitation of this study is that the results of our analysis were based on 
single NT-proBNP measurements at each time point so that day-to-day variability could 
not be assessed. We may have introduced some bias into our results by restricting the 
trajectory analyses to those subjects who survived and remained in the study for at least 
three years of follow-up. Although we detected differences with respect to age and LV 
function between those included and those censored, there was no statistically significant 
difference with respect to the baseline levels of NT-proBNP (Appendix 10).   
 
Our study consisted mostly of men of European ancestry. Case numbers were 
insufficient to perform separate analyses among women. We were not able to examine 
the association of NT-proBNP with each of the single adverse events: fatal myocardial 
infarction, fatal stroke, non-fatal myocardial infarction, and non-fatal stroke due to the 
low number of events in each group. We also did not assess the new-onset of heart failure 
in this population. In addition, not all patients may participate in cardiac rehabilitation, so 
that we could be missing the most severe cases in our cohort64, affecting the 
generalizability of the results. Nevertheless, this should not affect the internal validity of 
our data, suggesting also that the true prognostic value of NT-proBNP may indeed be 
stronger. Last, we lacked information about structural and functional changes of the heart 
at one- and three-years follow-up so that we were not able to explore the association of 
the respective changes of NT-proBNP and the cardiac phenotypes in this study 
population. 
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Conclusion 
Among patients with stable coronary heart disease, NT-proBNP levels measured 
one year after the acute event not only remain associated with the onset of a subsequent 
CVE but also act as an important prognostic factor providing better discrimination and 
reclassification of subjects according to their risk for a subsequent adverse CVE when 
compared to baseline values obtained shortly after the acute event. We also showed that 
the three-year trajectory of NT-proBNP was associated with the onset of a subsequent 
event. These results support the prognostic value of obtaining serial measurements of this 
biomarker in the settings of the secondary prevention in order to be able to identify 
subjects a high risk for a further event, who could benefit from closer follow-ups 
including the implementation of possible novel CVD protective modalities118, 119.  
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Table 12. KAROLA cohort study population characteristics. 
Study sample, n 735 
Age (years), mean±SD 59.2±7.9 
Male, n (%)  621 (84.5) 
Body Mass Index (kg/m2), mean±SD 27.0±3.5 
Body Mass Index (categories), n (%)  
Normal weight  203 (27.6) 
Overweight  406 (55.2) 
Obese  126 (17.1) 
Smoking, n (%)  
Never smoker  246 (33.5) 
Ex-smoker  463 (63.0) 
Current smoker  26 (3.5) 
Status post Myocardial Infarction, n (%) 371 (50.5) 
Status post Coronary Artery Bypass Graft, n (%) 368 (50.1) 
History of Diabetes, n (%)  120 (16.3) 
Left Ventricular Function, n (%)  
Normal  406 (55.2) 
Mild depression  179 (24.3) 
Moderate depression  106 (14.4) 
Severe depression  44 (6.0) 
Blood Pressure*, n (%)  
0 points  477 (64.9) 
1 point  126 (17.1) 
2 points  118 (16.1) 
3 points  14 (1.9) 
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Table 12 (cont.). KAROLA cohort study population characteristics 
Total cholesterol (mg/dl), mean±SD 168±32 
HDL-cholesterol (mg/dl), mean±SD 40±11 
Creatinine (mg/dL) 
Center 1 mean±SD 1.05±0.41 
Center 2 mean±SD 0.83±0.20 
Use of statins, n (%) 566 (77.0) 
   
NT-proBNP (pg/mL), median [Q1, Q3]  Baseline One year 
Female  
704.1  
[361.9, 1758.0] 
299.0  
[126, 496.0] 
  Male 
530.8 
[277.9, 1032.0] 
174.0  
[85.7, 369.0] 
*according to Framingham Risk Score chart for 10 years risk for coronary heart 
disease 
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Table 13 NT-proBNP distribution at baseline and at one-year follow-up according to 
various sociodemographic characteristics, cardiovascular risk factors, and medication 
at baseline.  
  Baseline One-year follow-up 
 
n 
NT-proBNP 
(pg/mL) 
Median 
p value* 
NT-proBNP  
(pg/mL) 
Median 
p value* 
Age (years) 
30-39 13 185.0 
<0.001 
50.6 
<0.001 
40-49 90 401.2 101.0 
50-59 208 418.2 134.0 
60-70 424 682.7 264.5 
Sex  
Male 621 530.8 
<0.001 
174.0 
<0.001 Female 114 704.1 299.0 
Body Mass Index (kg/m2) 
< 25 203 637.4 
<0.001 
256.0 
<0.001 
25 – 29.9 406 542.3 168.0 
≥ 30  126 499.7 177.0 
Smoking  
Never smoker 246 614.2 
0.114 
217.0 
0.164 
Ex-smoker 463 526.2 179.0 
Current smoker 26 713.8 161.0 
Status post Myocardial Infarction 
Yes 371 620.6 
0.004 
165.0 
0.204 No 364 509.4 204.5 
Status post Coronary Artery Bypass Graft 
Yes 368 598.1 
0.025 
231.5 
<0.001 No 367 542.8 151.0 
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Table 13 (cont.). NT-proBNP distribution at baseline and at one-year follow-up 
according to various sociodemographic characteristics, cardiovascular risk factors, and 
medication at baseline. 
  Baseline One-year follow-up 
 
n 
NT-proBNP 
(pg/mL) 
Median 
p value* 
NT-proBNP 
(pg/mL) 
Median 
p value* 
History of Diabetes      
Yes 120 645.5 
0.185 
252.5 
0.064 No 615 553.5 176.0 
Left Ventricular Function 
Normal 406 410.2 
<0.001 
143.5 
<0.001 
Mild depression 179 580.0 199.0 
Moderate 
depression 
106 1065.5 342.0 
Severe depression 44 2010.0 741.5 
Blood Pressure±      
0 477 542.1 
0.150 
171.0 
0.018 
1 126 579.3 198.5 
2 118 639.6 233.5 
3 14 814.2 270.5 
Total Cholesterol (mg/dL) 
Q1 [90 – 145] 185 587.3 
0.774 
182.0 
0.668 
Q2 [146 – 164] 177 590.2 199.0 
Q3 [165 – 186] 192 522.4 165.0 
Q4 [187 – 334] 181 546.1 217.0 
HDL-Cholesterol (mg/dL) 
Q1 [5 – 32] 188 597.8 
0.656 
165.5 
0.593 
Q2 [33 – 38] 164 592.0 191.5 
Q3 [39 – 45] 194 542.5 204.0 
Q4 [46 – 118] 189 502.4 191.0 
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Table 13 (cont.). NT-proBNP distribution at baseline and at one-year follow-up 
according to various sociodemographic characteristics, cardiovascular risk factors, and 
medication at baseline  
  Baseline One-year follow-up 
 
n 
NT-proBNP 
(pg/mL) 
Median 
p value* 
NT-proBNP  
(pg/mL) 
Median 
p value* 
Standardized eGFR 
Q1 [-4.66, 0.55] 183 881.1 
<0.001 
361.0 
<0.001 
Q2 [-0.54, 0.16] 184 622.3 226.5 
Q3 [0.16, 0.68] 184 547.2 159.0 
Q4 [0.69, 2.37] 184 368.3 114.5 
Use of Statins  
Yes 566 543.9 
0.035 
173.5 
0.005 No 169 602.0 256.0 
* Kruskal-Wallis test and Wilcoxon signed rank sum test according to the number of 
levels in the variable 
± According to Framingham Risk Score chart for estimation of 10-year risk of coronary 
heart disease  
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Table 14. Crude analysis. 
 HR 95% CI 
Age (year)  1.05  [1.01, 1.08] 
Sex (male reference) 0.66  [0.33, 1.32] 
Baseline NT-proBNP (ln) 1.63 [1.33, 1.98] 
One-Year NT-proBNP (ln) 1.80  [1.48, 2.19] 
Body Mass Index (kg/m2)    
Normal weight (Ref) 1.00  
Overweight  0.61  [0.38, 0.99] 
Obese  0.99  [0.55, 1.81] 
Smoking   
Never smoker (Ref) 1.00  
Ex-smoker 1.03  [0.65, 1.63] 
Current smoker 1.39  [0.49, 3.97] 
History of Diabetes  1.46  [0.86, 2.50] 
Left Ventricular Function    
Normal (Ref) 1.00  
Mild depression 1.20 [0.69, 2.09] 
Moderate depression 1.46  [0.79, 2.69] 
Severe depression 3.78  [1.97, 7.25] 
Blood Pressure*  
0 points (Ref) 1.00  
1 point 1.84  [1.09, 3.13] 
2 points 1.31  [0.72, 2.40] 
3 points 4.28  [1.69, 10.81] 
Standardized eGFR  0.74  [0.61, 0.88] 
Total Cholesterol (mg/dl) 0.995 [0.99, 1.00] 
HDL-Cholesterol (mg/dl) 0.98  [0.96, 1.00] 
Use of Statins 0.91 [0.55, 1.50] 
*according to Framingham Risk Score chart for 10-year risk of coronary heart disease 
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Table 15. Cox-proportional hazards models evaluating the association between ln NT-
proBNP at baseline and at one-year follow-up and the onset of a secondary CVE. 
 
Multivariable 
Model* 
HR 95% CI 
Baseline levels of ln-transformed NT-proBNP (Model 1) 1.35 [1.04, 1.75] 
One year levels of ln-transformed NT-proBNP (Model 2) 1.60 [1.25, 2.07] 
Baseline levels of ln-transformed NT-proBNP (Model 3) 0.97 [0.69, 1.36] 
One year levels of ln-transformed NT-proBNP (Model 3) 1.63 [1.17, 2.27] 
*adjusted for age, sex, BMI, blood pressure, left ventricular function, current smoking, 
history of diabetes, total cholesterol, HDL-cholesterol, standardized eGFR, and use of 
statins (Baseline Prognostic Model). 
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Table 17. NT-proBNP levels over time.  
NT-proBNP 
(pg/mL), median [Q1, Q3]  
Baseline 
One-year 
follow-up 
Three-years 
follow-up 
Overall (n=613) 
569.4 
[296.7, 1114.0] 
192.0 
[95.7, 400.0] 
173.0 
[82.0, 376.0] 
Female (n=98) 
691.7  
[357.7, 1608.0] 
282.5  
[123.0, 478.0] 
239.5 
[126.0, 418.0] 
  Male (n=515) 
543.7 
[285.6, 1058.0] 
180.0 
[88.9, 369.0] 
153.0  
[77.4, 362.0] 
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Table 18. Cox-proportional hazards models evaluating the association between the 
estimated regression lines and the onset of a secondary CVE. 
 
Adjusted for age and sex Multivariable model*  
 HR 95% CI HR 95% CI 
Intercept 1.94 [1.48, 2.53] 1.93 [1.42, 2.63] 
Slope 8.19 [3.18, 21.09] 8.84 [3.23, 24.16] 
HR  for any increment in 
0.1 unit of the slope 
1.23 [1.12, 1.36] 1.24 [1.12, 1.37] 
* adjusted for age, sex, BMI, left ventricular function, history of diabetes, blood 
pressure. 
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STUDY 4 - CYSTATIN C AND THE ONSET OF A SECONDARY 
CARDIOVASCULAR EVENT 
 
Renal dysfunction is associated with changes in blood pressure, lipids, 
lipoproteins, homocysteine as well as C-reactive protein, promoting directly the 
progression of atherosclerosis26. Early stages of Chronic Kidney Disease (CKD) are 
associated with cardiovascular damage through uremic retention of solutes such as 
oxidative stress products and pro-coagulant factors. Simultaneously, vascular disease 
may promote a further deterioration of renal function, resulting in an increased risk for 
CVD among those with CKD25. CKD also has been shown to be associated with worse 
prognosis of CVD in several high-risk populations120. Simple creatinine measurements 
and/or creatinine clearance have been used routinely for the estimation of the glomerular 
filtration rate (GFR), which describes the flow rate of filtered fluid through the kidneys 
and is routinely used to assess the kidneys’ excretory function. However, creatinine levels 
depend on factors such as age, sex, race, and muscle mass121, 122. Moreover, the 
relationship between creatinine concentration and GFR is nonlinear, which leads to its 
overestimation at high levels and its underestimation at low creatinine values123. 
 
Recently, cystatin C has been shown to represent a potentially new and better 
marker of GFR, perhaps superior to creatinine and creatinine clearance124, 125. Cystatin C 
is a cysteine protease inhibitor involved in the metabolism of proteins120. It is produced in 
all nucleated cells at a constant rate and is freely filtered by the glomerulus and 
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metabolized by the proximal tubule.124, 126 Cystatin C levels do not depend on age, sex 
and muscle mass121, 122. In this context, one of the most promising uses of cystatin C 
would be as a marker of preclinical or early kidney disease among persons with 
creatinine-based GFR in the normal range (eGFR≥60 mL/min/1.73m2) but who have 
elevated cystatin C127.  
 
Cystatin C, in contrast to creatinine, was significantly associated with CVEs after 
adjustment for Framingham Risk Factors in a cohort of adults without clinical CVD121, 
and it has been described as a potential clinical marker providing complementary 
prognostic information in patients with CHD120, 121, 128. It also has been shown that 
increasing levels of cystatin C are associated with a worsening in cardiovascular risk 
profiles, suggesting perhaps that low-grade renal dysfunction and increased CVD risk 
might be mediated through common pathophysiological processes129. Even small changes 
in kidney function measured using cystatin C have been associated with a linear 
increased risk for heart failure and mortality compared to a J-shape association observed 
when using creatinine37, 130.  
 
The present study investigated the prognostic value of baseline levels of cystatin 
C compared to baseline levels of creatinine with respect to the onset of a secondary CVE 
in a cohort of patients with stable CHD who completed a cardiac rehabilitation program, 
after adjustment for well-established cardiovascular risk factors. We hypothesized that 
cystatin C levels measured at the end of the rehabilitation program show better prognostic 
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value than creatinine levels for the onset of a secondary CVE, when added to a model 
including established prognostic factors for secondary CVEs. 
 
METHODS 
Study Sample 
This study used the KAROLA cohort described on page 4. In addition to the 
inclusion/exclusion criteria already described, this study had the following exclusion 
criteria: censored observations due to lost to follow-up at baseline (n=137); number of 
affected vessels reported as 0 (n=14); baseline missing values for creatinine (n=34), 
cystatin C (n=12), lipid profile (n=7), systolic or diastolic blood pressure (n=2), and 
medications (n=2). Thus, a total of 994 participants remained for this analysis. 
 
Definition of Variables 
Covariates 
Baseline characteristics with respect to anthropometry, socio-demographic 
information, medical history and lifestyle factors were collected from a standardized self-
reported questionnaire applied at the beginning of the rehabilitation program. 
 
Blood measurements 
Baseline fasting blood samples were obtained at the end of the rehabilitation 
program (baseline values). The serum samples were brought within two hours into the 
laboratory for further processing. Samples were stored for up to one month at -20°C and 
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then transferred on dry ice to a -80°C freezer until analysis. All marker measurements 
were performed in a blinded fashion. 
 
Serum creatinine  
Serum creatinine levels (mg/dL) were measured by the kinetic Jaffe method 
(inter-assay coefficient of variation (CV) 2.4–5.7%) in center 1 and by an enzymatic p-
aminophenazone method (inter-assay CV 1.2–2.2%) in center 2.  
 
Cystatin C 
Serum cystatin C levels (mg/dL) were measured by immunonephelometry on a 
Behring Nephelometer II (inter-assay CV 2.4–4.3%).  
 
Statistical Analysis 
 Discrete variables are presented as counts and percentages, and continuous 
variables as arithmetic means and standard deviations or medians and/or quartiles based 
on their distribution, for the study population as well as stratified by quartiles of 
creatinine and cystatin C. Since creatinine levels were estimated using different analytic 
methods in both centers, creatinine levels were standardized to have a mean 0 and SD of 
1 for each sex in each center and pooled together for the overall sample. Cystatin C levels 
also were standardized to have a mean 0 and SD of 1 for each sex and pooled together for 
the overall sample. The average levels of creatinine and cystatin C by center and sex are 
provided in Appendix 10. A categorical variable for blood pressure was created as 
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defined in the Framingham Risk Score chart for 10-year risk for CHD101 (Appendix 5). 
Correlations between the variables were evaluated using the partial Spearman correlation 
coefficient.  
 
Assessment of prognostic value 
Using Cox-proportional hazards models we assessed the prognostic value of 
baseline levels of creatinine (Model 1), cystatin C (Model 2) and both measures together 
(Model 3) with a secondary CVE occurring during the follow-up after adding them to a 
defined prognostic model (Baseline Prognostic Model) including well established 
cardiovascular risk factors: age, sex, BMI, blood pressure, smoking, history of diabetes, 
total cholesterol, HDL-cholesterol, and use of statins. Follow-up started at the end of the 
cardiac rehabilitation program, for a maximum length of ten years (Figure 11). The 
assumption of proportional hazards was checked by including time-dependent 
interactions of each variable with the natural logarithm of survival time. We detected a 
violation of the proportional hazard for the confounder sex; thus, Cox-proportional 
hazards models were performed in SAS using sex as strata.  
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Figure 11. Study design for the assessment of the prognostic value of creatinine and 
cystatin C 
 
 
The strategy to assess model performance was the same as in Study 3. The 
likelihood ratio test was used to evaluate model performance. Based on the fact that the 
C-statistic is less useful with respect to evaluation of model improvement in risk 
prediction of future events, we assessed calibration using the Hosmer-Lemeshow chi-
square statistic, Net Reclassification Improvement (NRI) according to the risk strata of < 
10%, 10-20%, and > 20% of predicted probability for a secondary CVE103, 104, and 
Integrated Discrimination Improvement (IDI). Ninety-five percent confidence intervals 
(CI) were obtained for the NRIs and IDIs.  
 
Cystatin C 
(Model 1) 
Creatinine 
(Model 2) 
10 years follow-up 
Start cardiac 
rehabilitation 
End cardiac 
rehabilitation 
(Baseline) 
10 years 
follow-up 
// 
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As for Studies 1-3, we performed a secondary analysis among men. We 
considered two-sided p<0.05 as indicating a statistically significant result. All analyses 
were performed using SAS software, version 9.2 (SAS Institute Inc., Cary, North 
Carolina). 
 
RESULTS 
Table 19 shows the characteristics of the study population (n=994) at baseline. 
The mean age was 59.0 ± 7.9 years; 85.1% of the study sample were men; 55.0% were 
overweight, and 17.9% were obese. Only 4.6% reported current smoking at baseline. 
History of diabetes was present among 17.3% of the participants. In our cohort we 
detected differences with respect to age, sex, systolic blood pressure, history of diabetes, 
and HDL-cholesterol across creatinine quartiles (Table 20), as well as with respect to 
age, systolic blood pressure, history of diabetes, and use of statins across cystatin C 
quartiles (Table 21). 
 
During the follow-up period (median follow-up 9.9 years [interquartile range 6.1, 
10.0]), there were a total of 138 secondary CVEs. The IR was 17.8 secondary CVEs per 
1000 person-years [95% CI 15.0, 21.0].  
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Crude Analysis 
In the crude analysis standardized creatinine, standardized cystatin C, blood 
pressure, history of diabetes, and HDL-cholesterol were significantly associated with the 
onset of a secondary CVE (Table 22). 
 
Multivariable Analysis 
After addition to the baseline prognostic model, a one standard unit increase in 
standardized creatinine and standardized cystatin C were each associated with the onset 
of a secondary CVE with a HR of 1.13 [95% CI 1.01, 1.28] and of 1.15 [95% CI 1.03, 
1.28], respectively. When both biomarkers were in the model, we observed a pronounced 
attenuation of the HR for creatinine (HR 1.04 [95% CI 0.84, 1.28]) but not for cystatin C 
(HR 1.12 [95% CI 0.94, 1.34]) (Table 23). 
 
Assessment of prognostic models 
When assessing model performance, we did not detect a statistically significant 
improvement of the model fit according to the likelihood ratio test after addition of either 
standardized creatinine or both measures together. However, a statistically significant 
improvement of the model was achieved after addition of standardized cystatin C. None 
of the models showed a good calibration according to the Hosmer-Lemeshow statistic, 
i.e. none of the observed event rates matched the expected event rates according to the 
different models. The improvement of the C-statistic after addition of standardized 
creatinine was not statistically significant (p=0.19), but the addition of either standardized 
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cystatin C or both measures together was associated with a statistically significant 
improvement (both p-values = 0.04) (Table 24). 
 
When assessing reclassification, we observed a statistically significant 
improvement of both IDI and NRI, after addition of standardized cystatin C (Model 2) or 
both markers (Model 3) to the Basic Prognostic Model. In contrast, the addition of 
standardized creatinine (Model 1) was associated only with a statistically significant 
NRI. We observed a net reclassification of cases into a higher risk category (defined as 
net upwards reclassification) of 4.3% and 5.1% after addition of standardized cystatin C 
(Model 2) and both markers together (Model 3) respectively, compared to 3.6% 
reclassification achieved after addition of standardized creatinine (Model 1). The net 
reclassification of non-cases to lower risk categories (also called net downwards 
reclassification) was equal to 4.4%, 4.7% and 4.9% after addition of standardized 
creatinine, standardized cystatin C, and both markers, respectively (Table 24). 
 
In the secondary analysis restricted to men, neither creatinine nor cystatin C were 
statistically significant associated with the onset of a secondary CVE. We also did not 
detect an improvement in discrimination, calibration or reclassification when considering 
the biomarkers independently. A minimal improvement of NRI could be detected after 
considering both in the same model (Appendices 11 and 12).  
 
  
95 
DISCUSSION 
In our study sample creatinine and cystatin C were both associated with the onset 
of a secondary CVE after adjustment for well-established risk factors. However, when 
both biomarkers were in the same model, we observed an attenuation of the hazard for 
each one unit increase of standardized creatinine. With respect to the prognostic value, 
only the addition of standardized cystatin C to the Baseline Prognostic Model was 
associated with a statistically significant improvement of model performance, 
discrimination, and reclassification.  
 
Our results are consistent with the available literature. The prognostic value of 
both creatinine and cystatin C with respect to total mortality, cardiovascular deaths, and 
heart failure, stroke and MI was evaluated in the Cardiovascular Health Study, a 
community-based longitudinal study of adults 65 years of age and older. The authors 
reported that an increase of one unit standard deviation of cystatin C was statistically 
significantly associated with a 20 to 40% increased risk for each outcome among those 
with a normal kidney function, whereas creatinine was only weakly associated with 
cardiovascular death125. A study among subjects free of CVD showed that the addition of 
cystatin C, but not creatinine, to a model containing the traditional cardiovascular risk 
factors was associated with the onset of primary CVE, with a modest and a very small 
improvement in discrimination and reclassification, respectively121. The Atherosclerosis 
Risk in Communities (ARIC) Study including black and white individuals aged 46-64 
years found that levels of cystatin C had a stronger association and provided a statistically 
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significant improvement in reclassification with respect to total mortality and the onset of 
CHD, compared to estimated GFR using the CKD-EPI formula based on creatinine131. 
Further studies looked at the association of cystatin C with CV outcomes even after 
further adjustment for kidney function132, 133. A study in a cohort of patients referred to 
coronary angiography showed that cystatin C is robustly associated with fatal outcomes 
of all-cause and CVD mortality even after further adjustment for GFR based on 
creatinine134. 
  
Our secondary analysis restricted only to men showed a non-statistically 
significant association between cystatin C and the onset of a secondary CVE. These 
results are of particular interest knowing that differences in the association between 
cystatin C and outcomes such as total mortality have been described across the sexes in 
the general population. An analysis performed in the population-based Tromsø Study 
showed that among women cystatin C levels in the fourth quartile were associated with a 
38% increased risk of death as compared to the lowest quartile in multivariable analysis. 
Such an association was not detected in men. A possible interaction between cystatin C 
and cardiovascular risk factors such as age, systolic blood pressure and BMI across sexes 
was described as one of the possible pathophysiological processes129, 132. 
 
Cystatin C has received much attention as an alternative marker of kidney 
function, which seems to be able to capture subtle changes in renal function when 
compared to creatinine129, with stronger and more linear risk relationships than creatinine 
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for outcomes such as chronic kidney disease, CVE and all-cause mortality, especially 
when used for the estimation of the GFR135. This, together with the facts that a worsening 
in cardiovascular risk profiles can be seen by higher levels of cystatin C and that the 
detected associations are independent of glomerular filtration rate, has led to the 
hypothesis that cystatin C levels could also reflect other pathways, such as inflammation, 
that influence the risk for cardiovascular disease121 or the reduction of pro-atherogenic 
activity136, 137. Consistent with this hypothesis, there was minimal attenuation of the 
hazard related to standardized cystatin C in the present study when both biomarkers were 
in the prognostic model. Cystatin C also showed better prognostic value than creatinine 
with respect to model performance, discrimination and reclassification when compared to 
creatinine.  
 
Limitations 
Some limitations of our study warrant mention. First, we had a single 
measurement of creatinine and cystatin C, respectively, measured at only one time point. 
As a result, we could not evaluate intra-individual and day-to-day variability, which has 
been reported to be as low as 5.4-8.6% for cystatin C138, 139. Second, creatinine levels 
were measured with different methods in the two rehabilitation centers, so that we were 
not able to use creatinine or cystatin C based GFR as the exposure of interest. This is 
particularly relevant knowing that eGFR equations based on cystatin C might help to 
detect increased risk of adverse outcomes that are not detected with creatinine-based 
eGFR135. Instead we used standardized measurements for creatinine and cystatin C, 
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which might make it difficult to compare our results with those from other studies. Third, 
due to the low number of subjects and outcome events, only limited analyses could be 
performed among women. This is especially important since heart disease is the leading 
cause of death for women in the United States140 and almost two-thirds of women who 
die suddenly of coronary heart disease have no previous symptoms141. We also could not 
evaluate the associations of the biomarkers with specific CVEs such as stroke and MI as 
well as cardiovascular death. Last, due to the known low participation rates in cardiac 
rehabilitation, we could be missing the most severe cases in this cohort, which could 
affect the generalizability of the results. The possibility of selection bias also exists if 
such patients did not participate in the cardiac rehabilitation due to their kidney function. 
 
Conclusion 
Creatinine and cystatin C were shown to be associated with the onset of a 
secondary CVE. However, having both in the same model was associated with an 
attenuation of the effect for creatinine, but not for cystatin C. Consistent with our 
hypothesis cystatin C seems to be a better prognostic factor for the onset of a secondary 
CVE and perhaps could help to identify subjects at higher risk. Cystatin C may be not 
only a good marker for kidney function, but perhaps it may be involved in 
pathomechanisms behind the formation and progression of atherosclerotic plaques.  
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Table 19. KAROLA cohort study population characteristics at baseline. 
Study sample, n 994 
Age (years), mean±SD 59.0±7.9 
Male, n (%)  846 (85.1) 
Creatinine (mg/dL) 
Center 1 mean±SD 1.04±0.36 
Center 2 mean±SD 0.83±0.20 
Cystatin C (mg/L), mean±SD 1.11±0.33 
Body Mass Index (kg/m2), mean±SD 27.1±3.5 
Body Mass Index (categories), n (%)  
Normal weight  269 (27.1) 
Overweight  547 (55.0) 
Obese  178 (17.9) 
Smoking, n (%)  
Current smoker  46 (4.6) 
Blood Pressure, n (%)  
0 points 650 (65.4) 
1 point 165 (16.6) 
2 points 159 (16.0) 
3 points 20 (2.0) 
History of Diabetes, n (%)  172 (17.3) 
Total Cholesterol (mg/dl), mean±SD 168±32 
HDL-Cholesterol (mg/dl), mean±SD 39±10 
Use of Statins, n (%) 771 (77.6) 
* According to Framingham Risk Score chart for 10-year risk for coronary heart 
disease. 
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Table 22. Crude analysis. 
 HR  95% CI 
Age (year)  1.03 [1.01, 1.05] 
Standardized creatinine (one standard deviation) 1.13 [1.01, 1.26] 
Standardized cystatin C (one standard deviation) 1.19 [1.08, 1.31] 
Body Mass Index    
Normal weight (Ref) 1.00  
Overweight  0.82 [0.55, 1.21] 
Obese  1.23 [0.76, 1.97] 
Smoking   
Never smoker (Ref) 1.00  
Ex-smoker 1.33 [0.91, 1.94] 
Current smoker 1.44 [0.64, 3.22] 
Blood Pressure*   
0 points (Ref) 1.00  
1 point 1.46 [0.95, 2.25] 
2 points 1.54 [0.99, 2.39] 
3 points 2.68 [1.17, 6.16] 
Status post Myocardial Infarction  0.97 [0.70, 1.36] 
Status post Coronary Artery Bypass Graft  0.93 [0.67, 1.30] 
History of Diabetes  1.58 [1.06, 2.36] 
Total Cholesterol (mg/dL) 1.00 [0.99, 1.00] 
HDL-Cholesterol (mg/dL) 0.99 [0.97, 1.00] 
Use of Statins 1.01 [0.67, 1.51] 
*according to Framingham Risk Score chart for 10-year risk for coronary heart 
disease. 
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Table 23. Cox-proportional hazards models evaluating the association between 
standardized creatinine and standardized cystatin C and the onset of a secondary CVE. 
 
Multivariable Model* 
HR 95% CI 
Standardized creatinine (Model 1) 1.13 [1.01, 1.28] 
Standardized cystatin C (Model 2) 1.15 [1.03, 1.28] 
Standardized creatinine (Model 3) 1.04 [0.84, 1.28] 
Standardized cystatin C (Model 3) 1.12 [0.94, 1.34] 
* adjusted for age, sex, BMI, blood pressure, current smoking, history of diabetes, total 
cholesterol, HDL-cholesterol, and use of statins. 
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CONCLUSION 
 
The studies in this dissertation evaluated leisure time physical activity (LTPA), N-
Terminal pro-Brain Natriuretic Peptide (NT-proBNP), and cystatin C as possible 
predictors for a secondary cardiovascular event (CVE) in a German cohort of patients 
with stable coronary heart disease (CHD). The first study evaluated the association 
between self-reported levels of LTPA at one-year follow-up and the onset of a 
subsequent CVE. Our data showed that lower levels of LTPA practice reported one year 
after the initial event were associated with an increased risk for a secondary CVE, while 
the highest levels of LTPA practice were associated with a risk reduction after adjustment 
for identified confounders and for well-established cardiovascular risk factors. Similar 
results were observed when the analyses were restricted to male patients. When 
evaluating the effect of reverse causation by restricting the analysis to those reporting 
regular or good health at one-year follow-up, we detected an expected attenuation of the 
HRs towards the null but a still increased risk for those reporting seldom/never LTPA 
practice. With respect to the presence of misclassification, we observed a markedly low 
prevalence of those reporting seldom/never LTPA practice as well as a markedly high 
proportion of subjects reporting at least 5-6 times/week and 2-4 times/week of LTPA, 
when compared to what has been reported in the literature. Although this could reflect 
more consciousness about the benefits of physical activity in this population, we are 
concerned that the observed data indicate an effect of social desirability. However, since 
the information regarding the practice of LTPA was collected prior to the occurrence of 
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the secondary event, this would lead to a non-differential misclassification of the 
exposure, most likely causing a bias towards the null. In conclusion, the results of Study 
1 support the described protective effect of LTPA practice for a secondary CVE in 
patients with stable CHD.  
 
In our second study we investigated the association of life-course LTPA 
trajectories based on self-report and the onset of a subsequent secondary CVE. We 
observed within the age period 20-49 years a continuous decline in the prevalence of 
those practicing LTPA at least 5-6 times/week and a continuous increase in those 
reporting LTPA practice at 1-4 times/month. This change in the practice of LTPA 
associated with aging has been already described in the literature66. The proportion of 
subjects reporting seldom/never practice of LTPA over this age range was stable, and 
these participants had the highest average BMI, the highest proportion of diabetics as 
well as of subjects reporting low alcohol consumption. This group also contained a higher 
proportion of women compared to the other trajectory categories.  
 
Contrary to our hypothesis, we observed the highest hazard for a secondary CVE 
among those subjects with a steeper decrease of LTPA during the age period 20-49 years, 
followed by those with either sustained low or sustained high practice of LTPA over that 
age period. Having a continuous increase of LTPA during this age period showed a 
strong risk reduction for the onset of a secondary CVE. When evaluating the presence of 
reverse causation, we detected an expected attenuation of the effect of LTPA towards the 
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null; nevertheless, an increased risk for those with a stable seldom/never LTPA practice 
over the age period remained. Social desirability could also lead to an over-reporting of 
higher levels of LTPA practice during the age period 20-49. However, since the 
information regarding previous practice of LTPA was collected prior to the occurrence of 
a secondary CVE, one would expect a non-differential misclassification of the exposure, 
most likely causing a bias towards the null. In summary, the results of Study 2 emphasize 
that changes in levels of physical activity during the life course can still be associated 
with the onset of a subsequent cardiovascular event. Further studies collecting self-
reported and objectively measured information about physical activity over time are 
needed in order to improve our understanding of the impact of changes in behavior and 
the long-term benefits of practice of LTPA on secondary cardiovascular prevention. 
 
The third study examined the utility of longitudinal measurements of NT-proBNP 
in patients with stable CHD after an initial event. Our data showed a marked elevation of 
this biomarker in the acute phase after the initial event, reflecting the reversible increase 
in regional wall stress as a result of impaired left ventricular function41, 83, 98. These high 
levels tended to normalize at one-year follow-up, with a further decrease at three-years of 
follow-up. Our analyses showed that among those who remained event-free during the 
first year of follow-up NT-proBNP measured at one-year follow-up not only remained 
strongly associated with a subsequent CVE, even after adjustment for baseline levels, but 
also helped to improve the reclassification of subjects with respect to their risk for a 
secondary CVE. Including the three-year measurements of NT-proBNP allowed us to 
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estimate individual regression lines for NT-proBNP trajectories. We observed that among 
those who remained event-free during the first three years of follow-up even a 10% 
increase in the slope defining the trajectory was associated with the onset of a subsequent 
CVE. In this context it has been proposed that detected changes in NT-proBNP over time 
may reflect changes in LV-remodeling, ventricular dysfunction, severity of ischemia or 
atherosclerotic progression98, 112-116. Unfortunately, we lacked information about 
structural and functional changes of the heart at the one- and three-year follow-up so that 
we were not able to explore the association of the respective changes of NT-proBNP and 
cardiac phenotypes in this study population. In summary, the results of Study 3 support 
the prognostic value of obtaining serial measurements of NT-proBNP in patients with 
stable CHD. 
 
In the fourth study we examined the prognostic value of cystatin C, a novel 
biomarker for kidney function, versus creatinine with respect to the onset of a secondary 
CVE. In our data cystatin C levels measured at baseline were not only associated with the 
onset of a secondary CVE, but also its addition in a prognostic model containing well-
established risk factors showed an improvement in model performance, discrimination 
and reclassification. When both creatinine and cystatin C were in a model with well-
established risk factors, we observed an attenuation of the effect only for creatinine. This 
observation together with the reports that higher levels of cystatin C are associated with a 
worsening in cardiovascular risk profiles129 and that the detected associations between 
cystatin C and the onset of CVE are independent of glomerular filtration rate132-134 
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support the hypothesis that cystatin C levels could perhaps reflect pathways that influence 
the risk for cardiovascular disease such as inflammation121 or the reduction of pro-
atherogenic activity136, 137. 
 
We recognize the need for further clinical trials including subjects at high risk for 
a secondary CVE.  Nonetheless, we have been able to show that each of the evaluated 
prognostic factors, LTPA, NT-proBNP and cystatin C, might help to identify such a 
subgroup so that in the future new treatment modalities, new goals for risk factors, or 
new medications could be evaluated in the setting of secondary cardiovascular 
prevention. 
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APPENDICES 
 
 
Appendix 1 (Study 1). Cox-proportional hazards models evaluating the association 
between LTPA at one-year follow-up and a subsequent secondary CVE among men 
(n=695, 89 secondary CVEs). 
 
 
Adjusted for age Multivariable Model* 
 
HR 95% CI HR 95% CI 
Seldom/never  2.20 [1.06, 4.58] 1.55 [0.72, 3.33] 
1-4 times/month  1.30 [0.73, 2.30] 1.10 [0.60, 2.01] 
2-4 times/week (Ref) 1.00  1.00  
At least 5-6 times/week  0.92 [0.56, 1.52] 0.81 [0.49, 1.36] 
* adjusted for age, ln NT-proBNP, BMI, current smoking, alcohol consumption, history 
of hypertension, history of heart failure, history of diabetes, level of education, status 
post CABG, use of aspirin, ACE Inhibitors, beta-blockers, calcium-antagonists and 
diuretics. 
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Appendix 2 (Study 1). Cox-proportional hazards models evaluating the association 
between LTPA at one-year follow-up and a subsequent secondary CVE among those 
with self-reported regular or good health status at one-year follow-up (n=784, 92 
secondary CVEs).  
 
Adjusted for age          
and sex 
Multivariable Model* 
 
HR 95% CI HR 95% CI 
Seldom/never  1.62 [0.75, 3.52] 1.11 [0.50, 2.46] 
1-4 times/month  1.10 [0.61, 2.00] 0.90 [0.48, 1.67] 
2-4 times/week (Ref) 1.00  1.00  
At least 5-6 times/week 0.97 [0.60, 1.57] 0.88 [0.54, 1.44] 
* adjusted for age, sex, ln NT-proBNP, BMI, current smoking, alcohol consumption, 
history of hypertension, history of heart failure, history of diabetes, level of education, 
status post CABG, use of aspirin, ACE Inhibitors, beta-blockers, calcium-antagonists 
and diuretics. 
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Appendix 3 (Study 2). Cox-proportional hazards models evaluating the 
association between LTPA trajectories and a subsequent secondary CVE 
among men (n=725, 110 secondary CVEs) 
 
Adjusted for age Multivariable Model* 
Trajectories (group) HR 95% CI HR 95% CI 
1  
(sustained low level) 
1.32 [0.72, 2.44] 1.36 [0.73, 2.52] 
2  
(continuous increase) 
0.66 [0.37, 1.19] 0.65 [0.36, 1.18] 
3  
(steeper decline) 
1.63 [0.96, 2.75] 1.58 [0.93, 2.67] 
4  
(gradual decline) (ref) 
1.00  1.00  
5  
(sustained high level) 
1.42 [0.82, 2.46] 1.45 [0.84, 2.53] 
* adjusted for age, smoking, education, alcohol consumption. 
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Appendix 4 (Study 2). Cox-proportional hazards models evaluating the 
association between LTPA trajectories and a subsequent secondary CVEs 
restricted to those with regular or good health status at baseline (n=796, 
109 secondary CVEs). 
 
Adjusted for age and sex 
Multivariable 
Model* 
Trajectories (group) HR 95% CI HR 95% CI 
1  
(sustained low level) 
1.10 [0.59, 2.07] 1.15 [0.61, 2.17] 
2  
(continuous increase) 
0.72 [0.41, 1.28] 0.71 [0.40, 1.26] 
3  
(steeper decline) 
1.69 [1.00, 2.85] 1.66 [0.98, 2.81] 
4  
(gradual decline) (ref) 
1.00    
5  
(sustained high level) 
1.24 [0.70, 2.19] 1.28 [0.72, 2.26] 
* adjusted for age, smoking, education, alcohol consumption. 
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Appendix 5. Blood pressure according to the Framingham Risk Score Chart for 10-year 
risk for coronary heart disease. 
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Appendix 6 (Study 3). Cox-proportional hazards models evaluating the association 
between ln NT-proBNP at baseline and at one-year follow-up and the onset of a 
secondary CVE among men (n=621, 74 secondary CVEs). 
 
Multivariable Model* 
 HR 95% CI 
Baseline levels of log-transformed NT-proBNP (Model 1) 1.33 [1.01, 1.76] 
One year levels of log-transformed NT-proBNP (Model 2) 1.65 [1.25, 2.17] 
Baseline levels of log-transformed NT-proBNP (Model 3) 0.92 [0.63, 1.33] 
One year levels of log-transformed NT-proBNP (Model 3) 1.74 [1.21, 2.50] 
* adjusted for age,  BMI, blood pressure, left ventricular function, current smoking, 
history of diabetes, total cholesterol, HDL-cholesterol, standardized eGFR, and use of 
statins (Baseline Prognostic Model). 
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Appendix 10 (Study 4). Serum levels of creatinine and cystatin C stratified by 
center and sex (mean ± SD). 
 Center 1 (n=516) Center 2 (n=478) 
Creatinine (mg/dL) 1.04 ± 0.36 0.83 ± 0.20 
Cystatin C (mg/L) 1.18 ± 0.36 1.20 ± 0.32 
Among men (n=846) Center 1 (n=459) Center 2 (n=387) 
Creatinine (mg/dL) 1.04 ± 0.30 0.86 ± 0.19 
Cystatin C (mg/L) 1.18 ± 0.35 1.19 ± 0.30 
Among women (n=148) Center 1 (n=57) Center 2 (n=91) 
Creatinine (mg/dL) 0.99 ± 0.68 0.72 ± 0.21 
Cystatin C (mg/L) 1.18 ± 0.36 1.26 ± 0.41 
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Appendix 11 (Study 4). Cox-proportional hazards models evaluating the 
association between standardized creatinine and standardized cystatin C and a 
subsequent secondary CVE among men (n=846, 122 secondary CVEs). 
 
Multivariable Model* 
HR 95% CI 
Standardized creatinine (Model 1) 1.12 [0.99, 1.28] 
Standardized cystatin C (Model 2) 1.12 [0.99, 1.27] 
Standardized creatinine (Model 3) 1.04 [0.84, 1.28] 
Standardized cystatin C (Model 3) 1.12 [0.94, 1.34] 
* adjusted for age, BMI, blood pressure, current smoking, history of 
diabetes, total cholesterol, HDL-cholesterol, and use of statins. 
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